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CHAPTER I 
 
INTRODUCTION 
 
Coagulation 
 The formation of blood clots, coagulation, is an essential process for preventing 
blood loss following blood vessel injury. Coagulation is initiated by tissue or cellular  
damage which activates numerous plasma proteases, called factors (F), in serial fashion 
deemed the coagulation cascade.  The coagulation cascade is traditionally divided into 
the extrinsic or tissue factor pathway and the intrinsic or contact factor pathway.   
Following blood vessel injury damaged endothelial and subendothelial cells 
expose, or decript, tissue factor (TF) a transmembrane procoagulant protein.  TF then 
binds circulating FVII forming the TF-FVIIa complex.  The TF-VIIa complex can 
proteolytically activate FIX and FX into FIXa and FXa.  Activated FX can then associate 
with FVa and the FXa-FVa prothrombinase complex can convert FII to FIIa, also  known 
as thrombin1-3.  For activation, FXa proteolytically cleaves FII at two distinct sites, 
Arg273-Thr274 and Arg323-Ser324.  Single cleavage events give rise to intermediates 
prethrombin or meziothrombin, and dual cleavage of prothrombin results in formation of 
FIIa 4,5. 
Additionally, the intrinsic pathway of the coagulation cascade, also referred to as 
the contact factor pathway, can be initiated through FXII contact with negatively charged 
cell surfaces, proteins or even microparticles6.  FXIIa then activates FXI which 
subsequently activates FIX.  FIXa in complex with FVIIIa can facilitate the activation of 
FX and subsequent FIIa. The culmination of both pathways is the production of localized 
elevated concentrations of thrombin, which can then convert fibrinogen into fibrin forming 
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a hemostatic network. Additionally, thrombin activates platelets, which subsequently 
adhere to fibrin, forming the clot. 
 
Platelets 
 
Platelet biogenesis and structure 
Platelets are unique anuceate cellular particles derived from the megakaryocyte 
and are present only in mammals.  Megakaryocytes are polyploidy cells of hemotapoetic 
origin that reside in bone marrow7.  The prevailing theory of the mechanism by which 
platelets are formed involve megakaryocyte cytoplasmic maturation, migration to a blood 
vessel, followed by proplatelet formation and release.  First megakaryocytes repeatedly 
undergo endomitosis, a process in which the spindle poles do not pull apart during 
anaphase thus creating a single but polyploid nucleus (4n, 16n, etc…).  Endomitosis 
provides the nucleic acid, protein, and lipid necessary for the formation of the 
demarcation membrane system (DMS)8.  The DMS is a complex network of deeply 
invaginated membrane continuous with the megakaryocyte plasma membrane and is the 
source of proplatelet and platelet membrane9.  Proplatelets are filopodia-like extensions 
of the megakaryocyte DMS which break through bone marrow sinusoidal vascular walls, 
and once in the blood, the proplatelets are released and mature into platelets10.  
The mature platelet is an average of 3 µm in size and has an invaginous 
membrane much like it’s parent cell called the canalicular system.  Platelets are 
disposable cells and the whole population turns over every 7-10 days.  Platelets possess 
cellular organelles such as mitochondria and lysosomes however, they also contain 
specialized organelles including, glycosomes, alpha granules, dense granules, and the 
dense tubular system (DTS).  Glycosomes are intracellular vesicles filled with glycogen 
particles but, to date, have no associated function.  Alpha granules, the must abundant 
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organelle, harbors procoagulant proteins including: FV, P-selectin, and Von Willebrand 
Factor.  Defects in packaging alpha granules in the megakaryocyte give rise to Grey 
Platelet Syndrome, a condition where alpha granules are essentially empty leading to 
reduced platelet aggregation upon stimulation with a number of agonists and manifests 
as moderate bleeding in patients11,12.  Dense granules contain several second 
messengers and ions including, ADP, ATP, 5-HT, Mg2+, Ca2+ and polyphosphates which 
are released into the blood vessel upon agonist induced vesicle secretion13-15.  Secretion 
of both types of granules is dependent on a number of cellular processes most notably, 
Gq activation of Ca2+, DAG and PKC, and platelet SNARE machinery specifically, 
syntaxin 4, VAMP-3, and VAMP-816-21.  The release of intracellular calcium is controlled 
primarily by the DTS, a megakaryocyte endoplasmic reticulum derived organelle22-24.  
The DTS is also the location of protein disulfide isomerase, adenylate cyclase and 
prostaglandin synthesis25-27. 
 
 
Figure 1.  Platelet structure and signaling 
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Platelet signaling 
The two primary and most potent activators of platelets are collagen and 
thrombin. Platelets contact collagen as a consequence of subendothelial extracellular 
matrix exposure following vascular injury. Collagen signals through collagen receptors 
present on the platelet surface. Collagen can also interact with GPIb and αIIbβ3 integrin 
receptors through binding Von Willebrand Factor though GPIa/IIa and GPVI are the main 
platelet collagen receptors28.  GPIa/IIa is an integrin receptor and mediates adhesion to 
collagen and activates Src, Syk, FAK, and PLA2 signaling downstream of the receptor.  
GPVI, an immunoglobin family receptor, can initiate collagen adhesion and signaling to 
PLCγ causing calcium mobilization and subsequent platelet shape change29-33.  
Thrombin is introduced to the platelets through coagulation cascade initiation following 
vascular injury.  Thrombin binds at least 3 receptors on the platelet cell surface to elicit 
cellular responses including PAR1, PAR4, and GPIb. 
Upon stimulation platelet intracellular calcium, released mostly from the DTS, 
increases 10 fold34. Lysosomal-like calcium stores and store-operated calcium entry also 
significantly contribute to agonist induced elevations in intracellular calcium35-37. Calcium 
mobilization activates PKC leading to degranulation and release of several feed-forward 
molecules. Gq signaling activates PLCβ leading to thromboxane (TXA) generation in a 
cyclooxygenase, arachadonic acid-dependent manner. Upon granule release and TXA 
synthesis, several receptors on the platelet surface are subsequently activated in an 
autocrine, paracrine feed-forward manner to provide full platelet activation.  ADP, 
released by dense granule secretion, activates the P2Y1 and P2Y12 purinergic receptors 
on the platelet which are coupled to Gq and Gi respectively38,39.  Basal levels of cAMP 
provide an inhibitory tone to the platelet. For example, PKA activates Rap1GAP2 which 
regulates the small GTPase Rap1, a protein essential to fibrin receptor activation and 
platelet-fibrin interactions in a clot 40.  Gi signaling releases the inhibitory tone of cAMP 
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and helps prime the platelet for activation.  Along with ADP, 5-HT is released from 
platelet dense granules and can activate platelet 5-HT2A receptors. However, 5-HT2A 
agonism alone does not significantly aggregate platelets, rather it serves as a potentiator 
for other platelet agonists41.   
TXA activates the thromboxane A2 receptor which is coupled to Gq and G1242,43.  
The G12 family of heterotrimeric G-proteins activates Rho-GEFs, which subsequently 
activate Rho and Rho kinase. In platelets, Rho mediated activation of Myosin Light 
Chain kinase is essential for platelet shape change, especially filopodial extensions that 
increase surface area for fibrin and platelet contact44.   
The multiple pathways required for inside-out activation of the platelet fibrin 
receptor, αIIbβ3, have not been fully elucidated.  However, Gi signaling in conjunction 
with G12 or Gq is sufficient to fully activate αIIbβ3. Additionally, Rap1 plays a major role in 
αIIbβ3 activation45,46.  Thrombin as a primary mediator of platelet activation is unique from 
collagen as thrombin signaling can activate both Gq and G12 to initiate granule secretion, 
shape change, and inititate feed forward signaling to activate Gi thus fully engaging the 
platelet. Though platelet activation is essential to hemostasis following vessel injury, 
platelets also significantly contribute to thrombosis. Several therapeutics inhibit platelet 
activation with the goal of reducing blood vessel occlusion and thus subsequent tissue 
injury. 
 
Anti-platelet therapeutics 
 
Aspirin 
 Aspirin, or acetylsalicylic acid, targets cyclooxygenase (COX) and irreversibly 
inhibits the enzyme by acetylating serine 530 which blocks arachadonic acid access to 
the enzyme active site.  COX is responsible for the biogenesis of all eicosanoids 
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including inflammatory prostaglandins and leukotrienes.  The potent anti-platelet nature 
of aspirin, arising from aspirin consumption, is derived from inhibiting the formation of the 
eicosanoid thromboxane and thus feed forward signaling to TXA2 receptor.  A regular 
aspirin regimen is a standard of care for the prevention of myocardial infarction and 
secondary stroke. 
 
Purinergic receptor antagonists 
The Gi coupled P2Y12 receptor together with the Gq coupled P2Y1 receptor 
mediate feed forward platelet activation by ADP. The theinopyridine compounds, 
ticlopidine, clopidogrel (Plavix), and prasugrel are produgs which the active metabolites 
irreversibly bind to and inhibit P2Y12.  In recent clinical trials, prasugrel was comparable 
in safety to clopidogrel but had a faster onset to therapeutic range, and was more 
consistent in regards to compound mediated inhibition of ADP mediated aggregation47,48.  
Thienopryidine compounds alone and in conjunction with aspirin are commonly used 
after percutaneous coronary intervention and the placement of stents for the prevention 
of secondary cardiovascular events. 
 
Integrin αΙΙbβ3 inhibitors 
 The clinically used αIIbβ3 inhibitors all block fibrin binding to the receptor but have 
unique pharmacophores. Abciximab is the fragment antigen-binding (Fab) region of a 
monoclonal antibody directed towards αIIbβ3. Abciximab must be administered 
intravenously and interestingly displays a very short plasma half-life due to irreversible 
target binding and rapid clearance of un-bound drug. Abciximab also binds vitronectin 
receptors, which are present not only on platelets but also on endothelial cells and 
smooth muscle. Eptifibatide is a cyclic peptide mimetic of barbourin, a rattlesnake venom 
peptide that exhibited high selectivity for αIIbβ3 inhibitory action over other integrin 
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receptors in a venom screen49.  Eptifibatide is a readily reversible, high affinity αIIbβ3 
blocking drug that is also administered intravenously. A recent trial comparing 
eptifibatide to abciximab demonstrated the two drugs were equally efficacious as an 
adjunct to percutaneious intervention as measured by ST-segment resolution50. Tirofiban 
is a non-peptide small molecule inhibitor of αIIbβ3 discovered through virtual screening51. 
Although tirofiban is much cheaper than abciximab, there are conflicting reports as to the 
efficacy and safety profile compared with that of abciximab52,53. 
 
Thrombin: The hemostasis enzyme 
 
Enzyme overview  
Hemostasis is literally blood (hemo), standing still (stasis), the cessation of blood 
loss while blood continues to  flow. Thrombin, or Factor IIa, is the seminal protease 
formed during coagulation and is essential for the process of hemostasis. The primary 
mechanism for hemostasis is the formation of a platelet-fibrin plug that prevents 
continued blood loss at a site of vessel injury. Thrombin is a 36 kDa vitamin K dependent, 
trypsin-like serine protease that cleaves many protein substrates C-terminal to arginine 
(R) at a D-P/L-R-S consensus site54. Thrombin plays two essential roles in hemostasis. 
Thrombin enzymatically processes fibrinogen at four distinct arginine-glycine bonds to 
form fibrin monomers. Fibrin monomers subsequently crosslink and form a fibrin clot to 
which platelets can adhere to at a site of vessel injury. Thrombin also directly activates 
platelets via protease-activated receptors (PARs) on the platelet surface. Thrombin 
mediated platelet activation is robust and induces shape change, secretion, activation of 
integrin αIIbβ3 and aggregation55,56. As the central component to clot formation, thrombin 
activation is tightly regulated by anti-coagulants. Insufficient thrombin activity can cause 
severe hemorrhage, however, excess thrombin activity (or insufficient activity of 
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regulators of thrombin) results in hypercoaguable states. Thrombosis (vessel occlusion) 
caused by intra-vessel clot formation is often a result of hypercoaguable states and is 
the root cause of stroke, myocardial infarction, and thromboembolism. Since clot 
formation is dependent on thrombin formation in vivo, thrombin is an obvious target for 
anticoagulants. 
 
Thrombin regulation 
Thrombin is regulated by a number of direct and indirect mechanisms. As small 
amounts of thrombin are generated, it can directly activate FV and FVIII in a feed 
forward manner to produce additional thrombin57,58.  Thrombin-mediated activation of 
platelets initiates platelet FVa, release which participates in the prothrombinase complex, 
forms more thrombin but is resistant to anti-coagulant proteins59-61.  Thrombin also 
negatively regulates its own production using thrombomodulin.  Thrombomodulin is a 
single transmembrane protein that when bound by thrombin inhibits thrombin-mediated 
fibrin formation and activation of factor V62.  Thrombomodulin-bound thrombin activates 
Protein C (PC) a potent anti-coagulant that inhibits both FVIIIa and FVa, preventing 
activation of FX and thus thrombin formation63.  Non clot-bound thrombin is also 
susceptible to circulating anti-thrombin (AT)64.  AT, a serpin family protease inhibitor, 
binds heparin co-factor and the AT-heparin complex directly inhibits thrombin’s active 
site in an exosite II-dependent manner63.   
 
Thrombin inhibitors 
 
Warfarin 
 Warfarin is often the standard of care for secondary prevention of stroke or 
myocardial infarction. Warfarin is also used to treat recurrent venous thrombosis and 
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venous thromboembolism. Warfarin is of the coumadin chemical class which are rodent 
poisons and are effective as such using the same anticoagulant mechanism.  
Coagulation factors require gamma-glutamate residues near their N-terminus to bind 
calcium, which is required for binding procoagulant surfaces and thus efficient 
coagulation.  Glutamate is post translationally modified mainly in the liver by gamma-
glutamyl carboxylase using vitamin K in the process, which subsequently becomes 
oxidized. Warfarin inhibits vitamin K epoxide reductase, which reduces vitamin K after 
oxidation effectively recycling the molecule.  Thus, warfarin depletes the available 
vitamin K and renders coagulation factors incapable of binding procoagulant surfaces.  
The severe bleeding effects of Warfarin, through this mechanism, are readily reversible 
by administering vitamin K. 
 
Factor Xa inhibitors 
A new class of anti-coagulants, FXa inhibitors, indirectly inhibits thrombin by 
preventing prothrombinase complex-mediated thrombin formation.  Rivaroxiban and 
Apixaban are both orally bioavailable with comparable dosing regimens and reversibly 
bind FXa.  Apixaban is approved for the prevention of stroke in patients with atrial 
fibrillation, excluding those caused by heart valve defects and was demonstrated as 
more efficacious than warfarin in preventing stroke with decreased prevalence of 
bleeding side effects65.  However, unlike warfarin, there are no antidotes for rivaroxiban 
or apixaban, and an overdose would prove lethal. 
 
Direct thrombin inhibitors 
Several inhibitors of thrombin are clinically useful for the management or 
prevention of thrombosis. Hirudin, the first identified non-endogenous thrombin inhibitor, 
is an enzyme secreted by leeches and is responsible for the anti-coagulant properties of 
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leech saliva66. Hirudin is a bivalent direct thrombin inhibitor, binding both the active site 
and exosite I to inhibit thrombin mediated fibrin formation67. Several direct thrombin 
inhibitors were designed with the same mechanism of action as hirudin including 
bivalirudin, lepirudin, and desirudin and are used when heparin is contraindicated.  Other 
direct thrombin inhibitors such as Argatroban and Dabigatran are univalent and only bind 
to the thrombin active site.  Dabigatran is a novel univalent direct thrombin inhibitor that 
is orally bioavailable and has similar endpoints for stroke and systemic embolism as 
warfarin for the treatment of atrial fibrillation68. 
Though thrombin inhibitors are an effective way to prevent thrombosis, all anti-
thrombotic agents carry an increased risk of bleeding.  A target downstream of thrombin 
in the coagulation cascade would be ideal since thrombin is involved in fibrin formation 
and without fibrin, hemorrhage occurs69.  The platelet, the other major clot constituent, 
harbors two thrombin receptor subtypes responsible for the cross-talk between 
coagulation and platelet activation.  These receptors may serve as better anti-thrombotic 
targets since even if inhibited, thrombin can continue to act on fibrinogen and preserve 
the fibrin network and collagen can continue to signal to the platelet at the site of vessel 
injury.  
 
 
Platelet thrombin receptors 
 
Introduction 
Davey and Luscher provided the first evidence that thrombin was a potent 
platelet activator capable of initiating platelet aggregation and nucleotide release70.  
Thrombin’s mechanism of action on the platelet was later described by Detwiler et. al. as 
initiating calcium mobilization in a time, and dose-dependent manner consistent with 
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agonist-receptor interaction71-73. Furthermore, hirudin competitively inhibited I125-thrombin 
binding to human platelets providing additional evidence for thrombin acting as a ligand 
for an unknown receptor on the platelet surface74.  
The first thrombin receptor, Protease-Activated Receptor-1 (PAR1), cloned in the 
lab of Dr. Shaun Coughlin using Xenopus laevis oocyte expression cloning, revealed a 
unique mechanism of thrombin-mediated receptor activation75. PARs are activated by 
proteolytic cleavage of the N-terminus, resulting in a new N-terminus which acts as the 
endogenous agonist or ‘tethered ligand’ for the receptors. The ‘tethered ligand’ 
mechanism creates essentially irreversible activation of PARs by proteases and thus 
unique challenges for drug development of PAR antagonists. The PARs are a family of 
type 1, or family A, G-protein coupled receptors comprising PAR1, PAR2, PAR3, and 
PAR4. Thrombin activates PAR1, PAR3, and PAR4 whereas PAR2 is activated by 
trypsin, tryptase, FVIIa, or FXa. The human platelet expresses PAR1 and PAR4, which 
are responsible for thrombin mediated platelet activation. Ergo, the platelet thrombin 
receptors are attractive targets for anti-platelet/anti-thrombotic therapeutics. 
 
PAR1 
 PAR1 is ubiquitously expressed in human tissues and is frequently referred to as 
the high affinity thrombin receptor due to the presence of a hirudin-like domain on the N-
terminus of the receptor which interacts with thrombin’s exosite I and allows thrombin to 
signal at picomolar concentrations75,76.  The thrombin cleavage site of PAR1 (LDPR/S) is 
located 41 amino acids from the N-terminus and shares homology with the thrombin 
cleavage site of Protein C (LDPR/I)75.  In addition to thrombin, PAR1 can be 
proteolytically activated by TF-FVIIa-Xa complex, FXa, Trypsin, Plasmin, Granzyme, and 
Matrix Metalloprotease-177-82.  Experimentally, PAR activation, in the absence of receptor 
cleavage, is accomplished by the use of a synthetic peptide corresponding to the first 6 
 12 
amino acids following the cleavage site (SFLLRN) 83,84.  
 PAR1 is a promiscuously coupled GPCR and signals through both G12 and Gq, to 
exert cellular effects43,84,85.  Though it has been proposed that PAR1 couples to Gi, it is 
indirect coupling, as evidence shows that without ADP secretion Gi signaling is not 
engaged downstream of PAR1. Additionally, it is well established that PAR1 activation 
causes ADP release via dense granule secretion86.  In platelets, G13 (which is of the G12 
family) is required for optimal platelet shape change, aggregation, and the formation of 
stable thrombi ex vivo87.  Similarly, it has been demonstrated that G12 in platelets, like in 
other cells, activates Rho kinase and myosin light chain phosphorylation, which 
canonically produces contractile events44. Gq deficient mice provide evidence that Gq 
signaling is required for thrombin induced secretion and aggregation but not shape 
change16.  PAR1 mediated Gq coupling produces rapid rises in intracellular calcium 
followed by rapid shut off.  Gq signaling downstream of PAR1 coupled with Gi signaling 
downstream of ADP receptors is sufficient to activate the integrin αIIbβ3 receptor so that 
platelets can bind a fibrin clot88. 
 In platelets, PAR1 rapidly desensitizes and remains unresponsive indicating a lack 
of a readily accessible pool of PAR1 in platelets89. PAR1 is desensitized via 
phosphorylation by the GRK family of kinases on serine and threonine residues in the C-
terminal tail of the receptor90,91. Due to the irreversible nature of PAR activation, PAR1 is 
not recycled back to the cell surface post desensitization, rather it is directed to the 
lysosome for degradation in order to terminate receptor signaling92,93. Interestingly, 
clatherin, rather than β-arrestin, is required for lysosomal sorting in a phosphorylation 
dependent manner though β-arrestin recruitment to PAR1 occurs and results in signal 
termination94,95.  
 Since PAR1 is absent from mouse platelets, knockout models fail to provide full 
insight into the function of human PAR1 in thrombosis and hemostasis. In rodents, PAR1 
 13 
plays a significant role in embryonic development as 50% of PAR1 null mice expire 
during gestation, a phenotype that can be reversed by endothelial specific expression of 
PAR1 using the Tie2 promoter, indicating that PAR1 function in the endothelium is 
critical for embryonic development96,97. PAR1 systemically is integral in mediating cross 
talk between coagulation and inflammation and it has even been suggested that PAR1 
activation can exacerbate viral infection98.  In addition an emerging role for PAR1 in 
metastasis is being appreciated. Given the physiological roles of PAR1, it is an ideal 
therapeutic target not only for the prevention of thrombosis but possibly inflammation as 
well. 
 Two PAR1 antagonists in clinical trials, Vorapaxar and Atopaxar, provide critical 
insight to the role of PAR1 in humans.  Atopaxar, also called E5555, has recently 
completed phase II clinical trials with intriguing results. Atopaxar is an orally bioavailable, 
reversible PAR1 antagonist that competes for PAR1 agonist peptide binding. Preclinical 
experiments in animal models demonstrated anti-thrombotic properties without an 
increased risk for bleeding99. In safety and tolerability studies, Atopaxar had a 23 hour 
half-life and the parent molecule was not subject to efficient renal clearance (less than 
0.2%)100. In the J-LANCELOT studies, Atopaxar administration inhibited PAR1-AP and 
collagen-mediated platelet aggregation but not ADP-mediated platelet aggregation ex 
vivo in healthy patients, patients with coronary artery disease, or patients with acute 
coronary syndrome. There was no significant difference in the incidence of major TIMI 
bleeding compared with placebo treated group however, Atopaxar treatment was 
associated with a dose-dependent increase in the incidence of hepatic dysfunction and 
QT prolongation101. It is questionable whether Atopaxar will continue forward to phase III 
clinical trials102.   
 Vorapaxar has completed phase III clinical trials with confounding results. 
Vorapaxar is a natural product analogue derived from Himbacine, a compound produced 
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in the bark of the Australian magnolia. Vorapaxar is orally bioavailable, demonstrates 
irreversible PAR1 antagonism, and apparently binds at the PAR1 peptide binding site103. 
The half-life of Vorapaxar ranges from 2.5 days to 6 days, which like aspirin, correlates 
with platelet turnover.  In accordance with the half-life, Vorapaxar inhibited greater than 
50% PAR1-AP mediated platelet aggregation ex vivo for up to 4 weeks after a single 
dose. There were no adverse effects reported on liver function or ECG readings during 
safety and tolerability studies104. The TRA-2P-TIMI 50 trial, excluding patients presenting 
with previous stroke, was completed and showed that PAR1 antagonism is effective in 
reducing cardiovascular death and ischemic events105-107. The TRA-CER trial was 
terminated due to an association of Vorapaxar treatment, in conjunction with standard of 
care (aspirin or clopidogrel), with an increased risk for intracranial hemorrhage. However, 
the bleeding side effect may be due to aspirin and clopidogrel exacerbating what is a 
mild bleeding effect of Vorapaxar on its own107.   
 
PAR3 
PAR3 is proteolyzed by thrombin and activates Gq however, any major role it 
plays in humans remains undetermined. A few studies describe a possible role for PAR3 
in pulmonary inflammation, though it may be a vestigial receptor in humans108,109.  PAR3 
null mice are protected against thrombosis however, these results are not directly 
translatable to human since mouse platelet PAR expression and signaling are not similar 
to human. On the mouse platelet PAR3 does not induce intracellular signaling and 
serves as a cofactor for PAR4, the signaling thrombin receptor. PAR3 knockout mice 
thus display prolonged bleeding times, and protection against ferric chloride-induced 
thrombosis of mesenteric arterioles and against thromboplastin-induced pulmonary 
embolism110-112.   
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PAR4 
 PAR4 together with PAR1 mediates thrombin signaling in platelets. PAR4 
expression is restricted to the megakaryocyte lineage, tumor cells, and perhaps specific 
populations of vascular cells113,114. PAR4 lacks the hirudin-like domain present in PAR1 
and is considered the low affinity thrombin receptor115. PAR4 as the low affinity thrombin 
receptor is consequently engaged by high concentrations of thrombin and thus subject to 
differential temporal engagement by thrombin. PAR4 shares just 33% amino acid 
sequence identity with other PAR members and has virtually no homology with any other 
PAR family members in the N or C-terminus116.  
Reports detail signaling differences between PAR1 and PAR4 indicating that 
although they are activated by the same endogenous agonist and couple to the same G-
proteins, the two platelet thrombin receptors signal in fundamentally distinct ways60,117,118. 
Whereas PAR1 mediated calcium signaling is rapidly desensitized via phosphorylation 
and internalization, PAR4 mediated calcium mobilization is prolonged119. There are also 
clear differences in the utilization of PI3K downstream of platelet thrombin receptors. 
PAR4 mediated aggregation is resistant to PI3K inhibition whereas PAR1-mediated 
aggregation is reversed by PI3K inhibition.  Furthermore, activation of αIIbβ3 is partially 
dependent on PI3K downstream of PAR1 but not PAR4. In addition, PI3K mediates 
PAR1 but not PAR4-induced calcium entry in human platelets, indicating interesting 
signaling differences independent of PAR-G-protein coupling118.  Platelets harbor, and 
upon stimulation, release FV from granules as well as produce platelet derived 
microparticles. PAR4-stimulated platelets release more FV and produce more 
microparticles than PAR1-stimulated platelets.  Additionally, PAR4 but not PAR1-
mediated microparticle production is highly dependent on Rho kinase. PKC appears to 
play a dual role in regulating microparticle production downstream of thrombin receptors. 
PKC inhibition enhances PAR1-mediated microparticle formation but inhibits PAR4-
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mediated microparticle production60. Together these findings present PAR4 as the more 
robust platelet activator in that they suggest a requirement for feed-forward signaling or 
inhibition of negative regulators for PAR1 to achieve full platelet activation, whereas 
PAR4 signaling alone is sufficient for full platelet activation.   
As the primary mediator of thrombin signaling on the mouse platelet, PAR4 null 
mice display markedly longer bleeding times than wild type and even PAR3 null mice.  
Similarly, PAR4 null mice are protected against ferric chloride-induced thrombosis of 
mesenteric arterioles and carotid arteries, and in a laser injury model of 
thrombosis111,120,121.  However, there are no data indicating a role for PAR4 in thrombosis 
and hemostasis in human as there are no clinical candidate molecules. YD-3 is the sole 
non-peptide, selective, PAR4 receptor antagonist and it’s utility as such has been 
demonstrated in platelet activation assays ex vivo as well as a mouse model of 
angiogenesis, but not thrombosis122-126. YD-3 is highly lipophilic and thus is not a suitable 
in vivo probe. Therefore the understanding of role of PAR4 in thrombosis and 
hemostasis remains far behind that of PAR1 due to the lack of potent, pharmacological 
tool compounds possessing favorable physiochemical properties and clinical candidates.   
 
Specific Aims 
The subsequent specific aims were followed in an effort to identify and design 
potent and selective PAR4 antagonists: 
Aim I – Improve the synthetic route of YD-3 for ease of future derivitization 
 a. Shorten the synthetic route of YD-3 
 b. Eliminate the inactive isomer of YD-3  
Aim II – Optimize indole-derived compounds for enhanced potency and 
 selectivity  
 a. Construct small molecule libraries around an indole scaffold 
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 b. Determine structure activity relationships by high-throughput screening 
 c. Determine the potency of lead molecules 
 d. Determine the mechanism of action of lead molecules 
Aim III – Characterize the role of PAR4 in platelets 
 a. Determine the role of PAR4 in models of thrombus formation 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
CHAPTER II 
 
 APC MODULATION OF PAR1 
 
Introduction 
 In the endothelium, PAR1 is the primary target of thrombin and activation of the 
receptor causes disruption of endothelial barrier integrity as well as production of pro-
inflammatory mediators127.  Since PAR1 is ubiquitously expressed and mediates several 
inflammatory and coagulant responses, PAR1 antagonism may provide effective 
protection against cardiovascular disease, inflammation, and cancer.  Activated protein 
C (APC) is an important regulator of coagulation. Protein C (PC), like coagulation factors, 
is a vitamin-K dependent zymogen glycoprotein that is proteolytically activated by 
thrombin.  Activation of PC by thrombin is most efficient in the presence of 
thrombomodulin (TM).  TM forms a complex with PC bound to the endothelial protein C 
receptor (EPCR) to which thrombin then binds TM and activates PC with high 
efficiency128-130.  APC binds Protein S and the complex proteolytically degrades 
coagulation factors Va and VIIIa, thus inhibiting the prothrombinase complex.  The 
importance of APC in maintaining hemostasis is underscored by the fact that individuals 
with heterozygous PC deficiency carry an increased risk of deep vein thrombosis and 
individuals presenting with homozygous PC deficiency develop fatal complications from 
sepsis if left untreated with exogenous APC131.  
 It has been reported that APC not only has anticoagulant functions, it also has anti-
inflammatory properties. APC inhibits nuclear factor-κB, tumor necrosis factor-α 
production, and apoptosis in an EPCR-and PAR1-dependent manner132.  EPCR is a type 
1 single pass transmembrane protein possessing a tripeptide C-terminal tail (Arg-Arg-
Gly).  Extracellularly, EPCR structurally resembles the major histocompatibility complex 
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class I (MHCI).  EPCR is highly expressed in vascular endothelium but EPCR is also 
found in other hematopoetic cells. APC binds EPCR using the vitamin-k dependent γ-
carboxyglutamic acid (Gla) domain128.  The APC-EPCR interaction is dependent on Ca2+ 
ion binding to the APC Gla domain likely to facilitate stabilization of the hydrophobic loop 
and aide interaction with EPCR.  The crystal structure of EPCR revealed a phospholipid 
binding site in the MHCI region, though the functional consequence of phospholipid 
binding is unknown133. EPCR is essential for anticoagulant functions evident as EPCR 
null mice are embryonic lethal and die before embryonic day 11 in part due to fibrin clot 
formation leading to placental thrombosis134.  Accordingly, overexpression of EPCR in 
mice is protective against thrombosis and sepsis135.  
 
APC-EPCR Modulation of PAR1 signaling 
 PAR1 activation elicits potent disruption of the endothelial monolayer. However, if 
EPCR is occupied by APC and PAR1 is subsequently activated, barrier protection 
occurs. PAR1-mediated barrier disruption depends on calcium mobilization, Rho 
activation, and activation of myosin leading to cellular contractile events136.  Gi signaling 
is inhibitory to contraction and therefore is barrier protective although exact mechanisms 
remain unknown.  Barrier enhancement may occur through PI3K-dependent activation of 
the Rac-GTPases, Tiam1 or Vav1, shown to mediate sphingosine-1-phosphate, Gi, 
dependent barrier protection137.  Interestingly, it has recently been shown that thrombin 
activation of PAR1 causes Rho activation, whereas APC activation causes Rac 
activation138. 
 The seminal observation of APC-protective signaling came from microarray data 
showing recombinant human APC inhibited gene transcription of a number of 
inflammatory mediators, including NFκb, while increasing anti-apoptotic mediators 
including eNOS139.  EPCR dependent activation of PAR1 by APC accounts for all 
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protective signaling, and APC signaling differs from that of thrombin140,141. Protective 
effects of APC were recapitulated using protease-dead APC and PAR1 synthetic peptide 
providing evidence that receptor occupancy, not enzymatic function, is necessary for 
producing protective effects142.  Since the concentration of APC required to elicit PAR1 
cleavage in vitro is 10,000 times higher than thrombin, a major criticism of APC-
mediated PAR1 activation143.  However, an occupancy model of APC-mediated PAR1 
activation nullifies said argument since theoretically PC (4 µg/mL plasma concentration) 
can substitute for APC.   
 Other differences between thrombin and APC-mediated activation of PAR1 have 
recently been demonstrated at the receptor level. APC, unlike thrombin, does not evoke 
internalization of PAR1 upon receptor activation though both agonists induce receptor 
phosphorylation138.  Caveolin is also essential to the protective phenotype of APC/PAR1, 
demonstrated by knockdown of CAV-1 in cells.  During APC mediated protective 
signaling, EPCR migrates out of caveolin which suggesting caveolin has an inhibitory 
role in protective signaling138,144.  The APC-EPCR complex has been shown to interact 
with PAR1, and sphingosine-1-phosphate receptor-1 (S1PR1). S1PR1 activation is 
essential for PAR1 protective responses145.  APC signaling has been shown in the brain 
by induction of calcium flux in human brain endothelial cells.  Furthermore, in mice, APC 
offers neuroprotection after ischemic injury independent of APC anti-coagulant 
activity132,146. 
 APC has proven to be an effective treatment of sepsis and may have additional 
benefits due to reported anti-inflammatory properties of APC.  Together these data 
suggest a receptor conformation unique to APC activated PAR1, which biases signaling 
to a protective phenotype through an unknown mechanism.  Understanding the 
mechanism by which APC confers anti-inflammatory effects on cells, primarily the 
endothelium, will provide insight into designing novel therapeutic agents.  Attempts were 
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made to delineate APC modulation of PAR1 in endothelial cells however, it appears that 
APC, PAR1, and thrombin produce similar rather than distinct cellular phenotypes.  
 
Materials and Methods 
 
Reagents 
 EA.hy926 cells were a kind gift from Dr. Cora-Jean S. Edgell. Human umbilical 
vein endothelial cells (HUVEC) were isolated within 48 hours after delivery and all data 
were collected from passages 1-5. Mouse Anti-ICAM-1 antibody and ATAP2 were 
purchased from Santa Cruz (Santa Cruz, CA, USA).  PAR1 activating peptide (PAR1-AP, 
TFLLRN), PAR2 activating peptide (PAR2-AP, SLIGKV) and PAR4 activating peptide 
(PAR4-AP, GYPGKF) were purchased from GL Biochem (Shanghai, China). APC and 
DEGR-APC were purchased from Haematologic Technologies (Essex Junction, Vermont, 
USA). The cyclic-AMP assay kit was from GE Healthcare (Connecticut, USA). Fluo4-AM 
is manufactured by life technologies (Grand Island, NY, USA). Rabbit anti-mouse 
horseradish peroxidase (HRP) conjugated antibody was purchased from Perkin Elmer 
(Waltham, MA, USA). TMB substrate was from Thermo (Rockford, IL, USA). 
 
Endothelial calcium mobilization assay 
 HUVEC (P1-P4) or EA.hy926 cells were seeded at a density of 50,000 cells/well 
on a 96 well Greiner (Monroe, NC, USA) black/clear bottom tissue culture treated assay 
plate  18-24 hours prior to assay. Cells were dye loaded for 1 hour with 2.5 μg/mL Fluo4-
AM in calcium assay buffer (1X HBSS with calcium and magnesium without phenol red, 
20 mM HEPES, 2.5 mM probenecid, 1 mM EGTA) 50 μL/well.  Dye loading buffer was 
exchanged for 90uL of calcium assay buffer without Fluo4-AM. Fluorescence 
measurements were recorded on a Molecular Devices Flexstation II 384 (Downingtown, 
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PA, USA) at 37 ºC. Agonists were added at 10X in calcium assay buffer into V-bottom 
compound plates and 10 μL of agonist was injected by the Flexstation into each well of 
the assay plate. Experiments reported were performed in triplicate, on the same plate. 
485:520 (ex:em) was measured each 1.55 seconds for a maximum of 4 minutes. Data 
represented as raw fluorescent intensity units (RFU) or as a percent of the maximum 
agonist response (value*100/max). 
 
Cyclic-AMP assay 
 Cells were seeded at a density of 200k cells/well in a 24 well cell culture dish.  
Cells were serum starved for 1 hour followed by pretreatment with 1 mM IBMX and 10 
μM forskolin for 5 minutes. Cells were subsequently stimulated with the indicated agonist 
for 5 minutes.  Media was aspirated to terminate signaling, the cell culture plate was 
wrapped in parafilm and stored at -80 ºC until assay. 147 μL lysis reagent 1B was added 
to each well and the plate was agitated for 10 minutes at room temperature. The 7.4 
protocol was followed exactly as recommended by the manufacturer.  
 
Evans blue albumin assay 
 Either HUVEC or EA.hy926 cells were plated on Corning (Corning, NY, USA) 24 
well Transwell culture dishes containing 3.0 µm pore size at a density of 10k cells/well 
and allowed to grow to confluence (optimized as 3 days). Cells were serum starved for 1 
hour prior to stimulation with the indicated agonist.  After stimulation, medium was 
removed from the top and bottom using the ‘flick and slam’ method or aspiration. Fresh 
growth medium containing serum was added to the lower chamber and Evans blue 
albumin medium (4% w/v Evan’s blue dye in DMEM supplemented with 10% fetal bovine 
serum) was added to he top chamber. After 10 minutes the transwells were removed 
and discarded. The medium from the lower chambers were removed, diluted 1:3 and 
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transferred to a 96 well black/clear bottom assay plate. The optical density at 650 for 
each well was determined via Molecular Devices SpectraMax 190 plate reader 
(Downingtown, PA, USA).   
 
ICAM-1 ELISA 
 Either HUVEC or EA.hy926 cells were seeded at a density of 10,000 cells/well on 
a 96 well Greiner black/clear bottom tissue culture treated plate 48 hours prior to assay.  
Fresh medium with serum was added to the cells 24 hour prior to assay. Cells were 
serum starved for 1 hour prior to assay.  Indicated agonists were added at 10X in serum 
free medium and cells were stimulated for the indicated period of time. Stimulation was 
terminated by washing each well 3 times with 200 μL of 1X PBST (0.1% triton X-100) pH 
7.4 and fixing in 100 μL/well 1% paraformaldehyde for 30 minutes. Cells were washed 
again 3 times in 200 μL PBST and 100 μL 5% milk blocking solution was added for 45 
minutes followed by another wash. 50 μL of 1 μg/mL mouse anti-ICAM-1 antibody was 
incubated with the cells for 45 min followed by a wash. Secondary anti-mouse HRP 
antibody was added at 1:2000 dilution for 40 minutes followed by another wash.  50 μL 
of TMB substrate was added allowed to incubate with the cells for 5 min and the optical 
density at 650 nm was read immediately on a plate reader. Data reported as fold 
baseline/non-stimulated response.   
 
Results 
 
PAR1 is the primary thrombin receptor in endothelial cells 
 In order to determine which protease activated receptors signal in endothelial cells, 
tethered ligand peptides directed towards PAR1, PAR2, or PAR4 were used to stimulate 
cells and calcium mobilization was measured.  HUVEC mobilized calcium in response to 
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PAR1-AP but not PAR4-AP (Figure 1A).  Similarly, EA.hy926 cells responded to PAR1-
AP and PAR2-AP but not PAR4-AP (Figure 1B).  These data indicate that endothelial 
cells have functional PAR1 but not PAR4.  Furthermore, in EA.hy926 cells the PAR1 
cleavage blocking antibody ATAP2 is able to abolish thrombin (Figure 1C) but not PAR1-
AP (Figure 1D) mediated calcium mobilization.  These data indicate that in endothelial 
cells PAR1, and not PAR4, is the primary receptor responsible for thrombin receptor 
signaling.  Alternatively, PAR4 may be present in endothelial cells but may not couple to 
Gq147. As expected, PAR1-AP is far less potent (EC50=46.9 ± 0.1 μM) than thrombin 
(EC50=2.3 ± 0.4 nM) at eliciting calcium mobilization. 
 
APC elicits calcium mobilization 
 Allosteric modulation of GPCRs may alter receptor coupling to heterotrimeric G-
proteins and PAR1 reportedly to couples to Gq, Gi, and G12, thus if APC is allosterically 
modulating PAR1, signaling effectors downstream of these G-proteins may also be 
altered.  EA.hy926 cells were stimulated with increasing concentrations of thrombin or 
APC.  Both APC and thrombin initiate calcium mobilization alone, though APC is 
significantly less potent and less efficacious than thrombin by greater than 100-fold 
(Figure 2).  To ensure that the calcium response from APC was not due to contaminating 
traces of thrombin from the manufacturers APC preparation, 0.4 nM bivalirudin was 
added to this and all subsequent experiments using APC as an agonist.  
 
APC does not significantly desensitize PAR1  
 To determine the effectiveness of PAR1 agonists in desensitizing PAR1-initiated 
calcium mobilization, thrombin, APC, and PAR1-AP were tested. Thrombin (Figure 3A) 
and PAR1-AP (Figure 3C) were capable of desensitizing PAR1 calcium mobilization. 
APC did not efficiently desensitize PAR1-AP at 20 nM concentration (Figure 3B).   
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Figure 1.  PAR1 is the primary thrombin receptor in endothelial cells.  A. HUVEC 
were treated with increasing concentrations of either PAR1-AP (black square) or PAR4-
AP (grey triangle) and calcium mobilization was measured.  Data represented as raw 
fluorescence intensity.  mean±S.E.M, n of 1 in triplicate.  B.  EA.hy926 cells were treated 
with either PAR1-AP (black square), PAR2-AP (grey triangle), or PAR4-AP (open 
triangle) and calcium mobilization was measured.  Data presented is an n of 1 
mean±S.E.M, performed in triplicate.  C. EA.hy926 cells were pretreated with assay 
buffer (black square), 2.5 μg/mL mouse IgG (dark grey triangle) or ATAP2 antibody (light 
grey triangle) for 20 minutes prior to stimulation with the indicated concentrations of 
thrombin.  D. EA.hy926 cells were pretreated with assay buffer (black square), 2.5 
μg/mL mouse IgG (dark grey triangle) or ATAP2 antibody (light grey triangle) for 20 
minutes prior to stimulation with the indicated concentrations of PAR1-AP.  Data 
represented is mean±S.D. n of 1 in triplicate.   
 
 
 These data indicate that 20 nM APC is ineffective at desensitizing PAR1-AP either 
acutely or over time.  APC is only weakly efficacious at mobilizing calcium at 
supraphysiological concentrations. To test the aforementioned EPCR occupancy theory, 
protease dead APC, DEGR APC, which is chemically modified at the active site and thus 
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proteolytically inactive, was used in place of APC. DEGR APC, was added to the cells 
and allowed to bind for 1 hour. Control tests were previously performed with purified 
DEGR APC to confirm there was no enzyme activity (data not shown).  PAR1 was 
subsequently stimulated with PAR1-AP and calcium mobilization was measured. DEGR 
APC treatment does not alter the potency or efficacy of PAR1-AP mediated calcium 
mobilization in HUVEC or EA.hy926 cells (Figure 3D). These data indicate either the Gq 
pathway is not modulated by APC or APC-EPCR does not modulate PAR1 signaling. 
 
 
Figure 2.  APC elicits calcium mobilization.  EA.hy926 cells were stimulated with the 
indicated concentrations of either thrombin or APC and calcium mobilization was 
measured.  Data represented is raw relative fluorescent intensity units, n of 1 performed 
in triplicate mean±S.D.   
 
 
PAR1 activation does not reduce cellular cAMP 
 To investigate whether Gi signaling was altered downstream of PAR1, total cellular 
cAMP levels were measured.  Forskolin increased cAMP levels approximately 3-fold 
over basal (Figure 4).  Thrombin and APC non-significantly decreased forskolin 
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stimulated cAMP in endothelial cells at the highest concentration.  These data indicate 
possible weak Gi signaling downstream of PAR1 activation, although agonist induced 
fluctuations in forskolin induced cAMP levels were not significant.  Again, APC signaling 
does not differ from that of thrombin. 
 
 
Figure 3. Desensitization of PAR1 calcium mobilization. EA.hy926 cells and Fluo4-
AM were used to test calcium desensitization. A. Cells were pretreated for either 10 
minutes (black squares) or 3 hours (grey triangles) with 20 nM thrombin followed by 
stimulation with indicated concentrations of PAR1-AP. Data represented is an n of 2 in 
triplicate mean±S.D. B. Cells were treated for 10 minutes (black squares) or 3 hours 
(grey triangles) with 20 nM APC prior to stimulation with increasing concentrations of 
PAR1-AP.  Data presented as n of 1 in triplicate mean±S.D. C. Cells were treated for 10 
minutes (black squares) or 3 hours (grey triangles) with 20 μM PAR1-AP prior to 
stimulation with increasing concentrations of PAR1-AP. Data represented is n of 2 in 
triplicate mean ±S.D. D.  Cells were incubated for 1 hour with 50 nM DEGR APC 
followed by treatment with increasing concentrations of PAR1-AP. Data is an n of 2 
performed in triplicate mean±S.D. 
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PAR1 agonists induce barrier permeability 
 Barrier permeability is a cellular contractile event dependent on calcium and Rho, 
a G12 effector.  It is reported that barrier permeability induced by PAR1 agonism is 
counteracted by pretreatment with APC142.  Attempts to reproduce barrier protection by 
APC failed to produce similar results to the literature.  The data in Figure 5 add controls 
that establish the acute effects of any PAR1 agonist on barrier permeability. APC (non-
significantly), PAR1-AP, and thrombin each induced barrier permeability within 10 
minutes of stimulation (Figure 5).  Since APC shares the same cellular phenotype as 
PAR1-AP and thrombin, these data support the hypothesis that APC is a low efficacy 
PAR1 agonist.   
 
 
 
Figure 4. PAR1 activation by APC or thrombin does not effectively reduce cellular 
cAMP.  1 mM IBMX treated EA.hy926 cells were stimulated with either 10 µM forskolin 
alone (0 nM) or 10 µM forskolin and the indicated concentration of thrombin and APC. 
Basal cAMP levels are represented as mean±standard deviation (solid horizontal 
line±dotted horizontal lines).  Bar graph presents data as an n of 2 performed in 
duplicate mean±S.D. 
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APC and thrombin inhibit TNFα induced ICAM-1 surface expression  
 In an attempt to reproduce findings from a recent manuscript, TNFα induced cell 
surface ICAM-1 expression was measured in EA.hy926 cells and HUVEC 148.  Both APC 
(Figure 6A) and thrombin (Figure 6B) significantly decreased TNFα-mediated ICAM-1 
expression. Both APC (Figure 6A) and thrombin (Figure 6B) significantly decreased 
TNFα-mediated ICAM-1 expression.  When TNFα and thrombin were added together 
(Figure 6B, 0’) thrombin prevented TNFα from up-regulating ICAM-1 over basal levels. 
To ensure that the differences in the time dependence was not due to the enzymes 
becoming inactivated, APC and thrombin were refreshed by media exchange every hour 
prior to TNFα stimulation.  These data do not support the hypothesis that APC is 
cytoprotective and thrombin is not.  Rather, these data are in agreement with APC being 
a low potency, low efficacy PAR1 agonist.   
 
 
Figure 5.  Barrier permeability is enhanced by APC, PAR1-AP, and thrombin.  
EA.hy926 cells were treated with 40 nM APC (p=0.086), 20 μM PAR1-AP (p=0.049) or 
10 nM thrombin (p=0.0002) for either 10 minutes or 180 minutes prior to determination of 
barrier disruption via Evans Blue Albumin assay. Data presented as fold change over 
basal permeability, n of 2 in duplicate, mean±S.D.  Solid horizontal line and dotted 
horizontal lines represent the mean and standard deviation respectively of basal 
permeability. Statistical analysis is unpaired one-tailed t-test versus basal, significant 
where indicated. 
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Figure 6. APC and thrombin inhibit TNFα-induced ICAM-1 surface expression. Cell 
surface ELISA was used to measure ICAM-1 surface expression.  Cells were serum 
starved for 1 hour prior to pretreatment with either APC or thrombin for the indicated 
amount of time followed by stimulation with 10 ng/mL TNFα for 2 hours.  A. Cells were 
treated with 20 nM APC in an n of 3 in triplicate mean±S.E.M. B. Cells treated with 20 
nM thrombin n of 3 in triplicate mean±S.E.M. Data presented as percent of 2 hour TNFα 
treatment.  Solid horizontal line and dotted horizontal lines represent the mean and 
standard deviation respectively of basal ICAM-1 expression.  Significant where indicated. 
***p<0.0003, **p<0.005 one sample t-test for deviation from maximal TNFα response. 
 
 
PAR1-mediated inhibition of ICAM-1 is concentration dependent 
 The concentration dependence of PAR1-mediated ICAM-1 inhibition was also 
examined. Endothelial cells were pretreated with APC, thrombin or PAR1-AP prior to 
stimulation with TNFα.  TNFα mediated ICAM-1 cell surface expression was severely 
inhibited by APC (Figure 7A), thrombin (Figure 7B), and PAR1-AP (Figure 7C) in 
EA.hy926 cells.  To ensure that the observed inhibition was not due to an artifact of 
testing in a transformed cell line, the same experiment was performed in HUVEC.  In 
primary cells, APC (Figure 7D) and PAR1-AP (Figure 7E) inhibited TNFα induced ICAM-
1 up-regulation in a concentration dependent manner.  These data, though contrary to  
reported phenomenon, indicate multiple PAR agonists, not only APC, can inhibit 
induction of a pro-inflammatory marker, ICAM-1.  
 31 
 
Figure 7.  APC, thrombin, and PAR1-AP inhibit TNFα-mediated ICAM-1 expression 
in a concentration dependent manner. A. HUVECs were serum starved for 1 hour, 
pretreated with the indicated concentrations of APC for 3 hours followed by stimulation 
with 10 ng/mL TNFα for 2 hours prior to measurement of cell surface ICAM-1 via ELISA. 
Data presented is n of 2 in triplicate mean±S.D. B. HUVECs were serum starved for 1 
hour, pretreated with the indicated concentrations of thrombin for 3 hours followed by 
stimulation with 10 ng/mL TNFα for 2 hours prior to assay. Data points are n of 1 in 
triplicate mean±S.D. C. HUVECs were serum starved for 1 hour, pretreated with the 
indicated concentrations of PAR1-AP for 3 hours followed by stimulation with 10 ng/mL 
TNFα for 2 hours prior to assay. Data points are n of 1 in triplicate mean±S.D. D. 
EA.hy926 cells were serum starved for 24 hours followed by pretreatment with either D. 
APC or E. PAR1-AP for 4 hours and subsequently stimulated with 10 ng/mL TNF for 4 
hours. Data points are n of 1 in triplicate mean±S.D. Solid horizontal line and dotted 
horizontal lines represent the mean and standard deviation respectively of basal ICAM-1 
expression. 
 
 
Summary and Discussion 
APC regulates calcium mobilization, cellular permeability, and ICAM-1 surface 
expression in a manner similar to thrombin and PAR1-AP.  These findings suggest APC 
could be a low efficacy thrombin receptor agonist and not necessarily a modulator of 
PAR1 signaling.  Thrombin is known to enhance calcium mobilization downstream of 
PAR1, however APC can also induce calcium mobilization likely through PAR1, though 
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that has not been definitively demonstrated.  Thrombin and PAR1-AP mediated PAR1 
desensitization is greater at 10 minutes of pretreatment than 180 minutes of treatment.  
These data indicate that re-sensitization, by enhancement of receptor reserve, takes 
longer than 10 minutes and even at 3 hours the potency of PAR1-AP desensitized by 
thrombin or PAR1-AP is lower than buffer-treated cells.  Similarly, thrombin treated cells 
don’t fully recover the maximal response at 3 hours.  This may be due to the ‘suicide’ 
nature of thrombin-mediated PAR1 activation and the tendency of PAR1 to be sent to 
the lysosome for degradation instead of recycling.  APC is reported to inhibit PAR1-
mediated barrier permeability, though those results were not reproducible.  However, 
PAR1, thrombin, and APC are capable of disrupting the barrier at 10 minutes. This 
‘protection’ could be due to receptor desensitization and not functional selectivity.  
Furthermore, the anti-inflammatory nature of APC, thrombin and PAR1 on TNFα-
mediated ICAM-1 cell surface expression is clear. These data suggest that PAR1 
activation by multiple agonists produce anti-inflammatory responses, thus APC is not 
necessarily acting as an allosteric modulator but as a low potency, weakly efficacious 
PAR1 agonist.  Alternatively, APC may not be an agonist of PAR1 but may be acting 
through another receptor that produces similar cellular responses as PAR1. 
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CHAPTER III 
 
HIGH-THROUPUT SCREENING FOR MODULATORS OF PAR1 
 
Introduction 
As the high affinity thrombin receptor on platelets, PAR1 is an attractive target for 
the development of anti-platelet and anti-thrombotic therapeutics. Several peptide 
mimetic and small molecule antagonists have been identified and characterized on 
human platelets149-152.   Antagonists of PAR1 reduce thrombin-mediated platelet 
aggregation, calcium mobilization, and phosphorylation of proteins ex vivo.  However, 
the number of clinical candidates to date remains few. Atopaxar, a reversible PAR1 
antagonist, is currently in clinical trials and a phase II study concerning its safety and 
efficacy in patients at risk for acute coronary syndrome has recently concluded.  There 
appeared to be a slight increase in risk of TIMI bleeding however, the largest concern 
was increased liver function abnormalities and QT prolongation102. Vorapaxar is the sole 
PAR1 antagonist that completed phase III clinical trials in patients and demonstrated a 
good safety profile.  Unfortunately for patients presenting with previous stroke, there was 
an increased risk for patients on Vorapaxar of developing intracranial hemorrhage noted 
in the TRA-2P-TIMI50 trial105-107.  Due to the irreversible nature of PAR activation, 
successful antagonists of PAR1 should possess a low off-rate or act allosterically at the 
receptor such that competition with the tethered ligand is possible.  In an effort to identify 
novel inhibitors of PAR1 mediated signaling, a high throughput screening assay was 
developed measuring intracellular calcium mobilization in a cell line.  A chemically 
diverse compound library was screened and select compounds were identified as 
inhibitors for PAR1 mediated calcium mobilization in an endothelial-like cell line, 
EA.hy926.  
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Materials and Methods 
 
Reagents 
EA.hy926 cells were a kind gift from Dr. Cora-Jean S. Edgell. Poly-Lysine treated 
Cellcoat Optilux, 384 well black / clear bottom were from BD biosciences (San Jose, 
California, USA). Fluo4-AM was purchased from Invitrogen (Grand Island, NY, USA). 
RWJ-56110 was synthesized in house.   
 
High throughput calcium assay 
EA.hy926 cells are seeded at the indicated density in 40 μL of Dulbecco’s 
Modified Eagle Medium containing 10% fetal bovine serum 18-24 hours prior to assay. 
Cells were dye loaded for 1 hour with 2.5 μg/mL Fluo4-AM in calcium assay buffer (1X 
HBSS with calcium and magnesium without phenol red, 20 mM HEPES, 2.5 mM 
probenecid, 1 mM EGTA, 0.1% BSA).  Cells were buffer exchanged into calcium assay 
buffer (without Fluo4-AM) prior to assay via the ‘flick and slam’ method or automated (for 
screening) by a BioTek ELx405 (Winooski, VT, USA).  Fluorescence measurements 
were recorded on a Functional Drug Screening System (FDSS) 6000, Hamamatsu 
(Hamamatsu, Japan) at 37 ºC. 20 seconds of basal fluorescence was recorded for each 
experiment prior to compound or agonist addition. Compounds (3X) and agonist (10X) 
were injected by the FDSS and occurred simultaneously across each plate. Compounds 
were allowed to incubate with cells for 5 minutes prior to agonist stimulation of calcium 
mobilization. Experiments reported were performed in at least triplicate, on the same 
plate. 480:540 (ex:em) was measured each second for a total of 4 minutes 20 seconds 
after agonist addition. The final concentration of DMSO in the assay, if present, was 
0.3%. Data was presented as % maximal agonist response or as a ratio of ex:em 
(480:540) max/basal fluorescence where basal is defined as ex:em at t0. 
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Results 
 
Optimization of cell density 
Optimization of a high throughput calcium mobilization assay was necessary 
prior to screening a library of compounds.  The cell line selected, EA.hy926, are primary 
HUVEC that have been transformed via hybridization with A549 (adenocarcinomic 
alveolar epithelial basal cells) cells.  Although the cells are hybridomas, they retain 
expression of most endothelial cells markers including PAR1 and PAR2153,154. EA.hy926 
cells were chosen as the model system not only because of the high level of 
endogenously expressed human PAR1, but also because it was serendipitously 
discovered that EA.hy926 cells displayed enhanced adherence to cell culture surfaces 
compared to epithelial cell lines such as HEK and CHO. Endogenous receptor 
expression was favored due to reduced inter-screen variability often seen in transient 
transfection cell assays.   
To establish the optimal signal:noise ratio for screening, EA.hy926 cells were 
seeded at several densities and stimulated with increasing concentrations of PAR1-AP 
using a descriptive 8-point concentration response curve (CRC).  An effective 
concentration for 80% of the maximal PAR1-AP response (EC80) was determined from 
these data.  PAR2-AP CRCs were also performed to determine an EC80 for counter 
screening future hits (Figure 1). The PAR1-AP maximal signal was similar at all cell 
densities. 8,000 cells/well allowed high PAR1 responses and little variability (Figure 1A). 
10,000 cells/well allowed high PAR2-AP responses but a modest PAR1-AP response 
(Figure 1B). At 12,000 cells/well there was the least amount of variability of any condition, 
however, the maximal signal for PAR1 was not as robust as at either 8,000 or 14,000 
cells/well (Figure 1C). The variability was slightly higher at 14,000 cells/well compared to 
8,000 cells/well but the highest signal:noise ratio for both PAR1-AP and PAR2-AP 
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mediated calcium responses was produced. Thus, subsequent optimization and 
screening was performed at the 14,000 cellular density (Figure 1D).  The estimated EC80 
for PAR1-AP and PAR2-AP was determined as 10-5.5 M and 10-5 M, respectively.  
 
 
Figure 1.  Optimization of EA.hy926 cell density for high-throughput screening.  
EA.hy926 cells were seeded at either A. 8,000 cells/well, B. 10,000 cells/well, C. 12,000 
cells/well or D. 14,000 cells/well in a 384 well plate in sextuplicate. Cells were plated 24 
hours prior to assay.  After dye loading for 1 hour, dye loading buffer was exchanged to 
45 μL calcium assay buffer. Agonists were added to the cells after 20 seconds of 
baseline fluorescent readings.  Data presented are fluorescent max ratio, n of 1, each 
point performed in triplicate; mean±S.D.   
 
 
Suitability of assay for high throughput screening 
At the optimal cellular density of 14,000 cells/well, a Z-factor was calculated to 
determine if the assay was suitable for screening.  Cells were treated with either assay 
buffer (vehicle) or the PAR1-AP EC80 and peak calcium was determined from the 
maximal fluorescence ratio as fold change versus the basal (defined as fluorescence at 
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t0).  A representative tracing from maximal PAR1-AP, EC80 PAR1-AP and vehicle treated 
wells is shown in Figure 2A. The Z-factor was calculated as described in Zheng et al. by 
performing a checkerboard assay using the EC80 of PAR1 and assay buffer as the signal 
and control respectively.  The Z-factor was 0.53 which is considered an ‘excellent assay’ 
for high throughput screening155.  
 
 
Figure 2. Suitability of Ca2+ assay for high throughput screening.  EA.hy926 cells 
were seeded at a density of 14,000 cells/well, cells stimulated with PAR1-AP, and 
calcium mobilization was measured by fluorescence intensity for 5 minutes.  A.  
Representative calcium tracings of raw fluorescent intensity of maximal PAR1-AP 
response (black), EC80 PAR1-AP response (grey), or vehicle (light grey). B. To 
determine the Z-factor, and thus the usefulness of the assay as a screening tool, cells 
were treated with either vehicle (calcium assay buffer) or EC80 PAR4-AP in 
checkerboard fashion in a 384 well plate. Data displayed as n of 1 with 192 replicates for 
each condition. Calculated Z-factor is 0.53.   
 
 
Antagonist proof of concept study 
A proof of concept study was conducted to ensure that the high throughput Ca2+ 
mobilization assay could identify a known PAR1 antagonist.  RWJ-56110 (RWJ), a well-
characterized PAR1 antagonist, was selected as the positive control.  RWJ is a peptide 
mimetic that behaves competitively at PAR1149. In the assay, RWJ was able to 
significantly inhibit the PAR1-AP EC80; therefore, the assay is suitable for identification of 
inhibitors of PAR1 (Figure 3). 
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Figure 3. Antagonist proof of concept study.  Cells were pretreated with either DMSO, 
buffer, or 10 μM RWJ-56110 for 5 minutes prior to stimulation with either an EC100 (10-3.5 
M) or EC80 (10-5.5 M) concentration of PAR1-AP. Data represented are raw fluorescent 
intensity of n of 1 with at least triplicate values for each data point.  Significant where 
indicated, unpaired two-tailed t-test versus DMSO-treated EC80 calcium response.  ### 
p<0.0001. 
 
 
Selectivity screening: agonist assessment 
To incorporate non-PAR family member calcium signaling into the counter 
screening efforts, an appropriate ligand for induction of calcium mobilization was needed.  
Endothelial cells express P2Y2, a purinergic Gq coupled GPCR responsible for the 
majority of ADP-mediated calcium mobilization in EA.hy926156.  Additionally, EA.hy926 
cells express Angiotensin type II receptor, a Gq coupled GPCR157.  ADP and angiotensin 
II (ANG II) were tested in the high-throughput calcium assay.  Both ADP and ANGII 
induced rapid intracellular calcium mobilization, indicative of Gq signaling. However, 
ANG II displayed weak potency and efficacy and thus was not suitable for counter 
screening (Figure 4A).  ADP produced robust calcium responses with an estimated EC80 
of 10-5M and was subsequently used in selectivity screening (Figure 4B). 
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Figure 4.  Counter-screen agonist selection. A. EA.hy926 cells were treated with 
increasing concentrations of either ADP or ANG II and calcium mobilization was 
measured. Data represented is an n of 1 performed in triplicate, mean±S.D. B. 
Concentration response curve of ADP stimulated EA.hy926 cells data presented is an n 
of 1 performed in triplicate mean±S.D.  
 
 
Screening for novel negative modulators of PAR1 signaling 
2000 chemically diverse structures were screened as part of the Vanderbilt 
Spectrum Collection (Figure 5). Aside from cell plating, the assay was fully automated 
via the resources in the Vanderbilt Institute of Chemical Biology High-Throughput 
Screening Facility.  The Labcyte Echo 550 was used for compound plate stamping 
thereby copying the spectrum collection into the compound plates used during screening. 
The ELx405 was used for both dye loading procedures as well as buffer exchange prior 
to assay.  Finally, the FDSS performed all liquid handling tasks and fluorescent 
measurements. The tracings of all compounds that displayed even weak inhibitory 
activity to the PAR1-AP EC80 were visually inspected as well as compounds that slowed 
the rate of calcium mobilization initiated by PAR1-AP.  Compounds displaying intrinsic 
fluorescence or weak agonism of calcium responses were triaged.  After careful analysis, 
10 compounds were suitable for validation and selectivity screening. 
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Fig. 5 cont. 
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Fig. 5 cont. 
 
Figure 5.  Spectrum collection screening results.  EA.hy926 cells were screened for 
inhibitory action against PAR1.  Cells were treated for 5 minutes with compounds from 
the Vanderbilt Spectrum Collection at 10 μM followed by stimulation with an EC80 of 
PAR1-AP.  Data are visually inspected, all demarked compounds were considered hits 
by meeting the following criteria: decreased either maximum PAR1-AP mediated calcium 
mobilization or the rate of PAR1-AP mediated calcium mobilization and did not possess 
intrinsic fluorescent properties. 
 
 
Validation and selectivity screening 
Compounds (plate.well) 2.K9, 2.LG, 2.O9, 5.L7, 6.E6, and 6.K9 did not generate 
reproducible inhibitory action against PAR1-AP mediated calcium mobilization.  
Compound 1.G3 appeared to be a general calcium inhibitor and thus not specific or 
selective for any agonist tested. Compound 4.E19 weakly selectively inhibited PAR1 and 
not PAR2 or ADP mediated calcium signaling.  5.E8 inhibited both PAR1 and PAR2 
mediated calcium signaling but not ADP and therefore may be a PAR family selective 
inhibitor. 7.I5 was intriguing because it weakly inhibited PAR1 mediated calcium 
response but potentiated ADP mediated signaling. 
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Figure 6.  Hit validation and selectivity screen. Cells were treated with the hit 
compounds from the screen for 5 minutes prior to stimulation with an EC80 of either A. 
PAR1-AP, B. ADP, or C. PAR2-AP. Several compounds did not reproduce inhibitory 
activity in the validation screen. Compound 1.G3 behaved as a general calcium inhibitor.  
Compound 4.E19 selectively inhibited PAR1-AP. 5.E8 selectively inhibited PAR1-AP and 
PAR2-AP. 7.I5 inhibited PAR1-AP responses but potentiated ADP mediated calcium 
mobilization. 
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Compound identities 
Compound 4.E19 (Figure 7A) is mitotane, a chemotherapeutic agent indicated 
for the treatment of adrenal carcinoma. Compound 5.E8 (Figure 7B) is plumbagin, a 
natural product possessing anti-cancer properties. Compound 7.I5 (Figure 7C) is benzyl-
dimethyl-tridecyl-ammonium, a lipid-like molecule with no associated function.   
 
 
Figure 7.  Identities of inhibitory compounds. A.  Compound 4.E19 is mitotane.  B. 
Compound 5.E8 is plumbagin. C. Compound 7.I15 is benzyl-dimethyl-tridecyl-
ammonium. 
 
 
Summary and Discussion 
Novel inhibitors of PAR1-mediated calcium mobilization have been discovered as 
a result of using endogenously expressed PAR1 in endothelial-like Ea.hy926 cells and 
fluo4-AM to screen a small molecule library. EA.hy926 cells are very adherent and are 
an excellent choice for automated high-throughput screening assays. The high-
throughput screen was designed and analyzed to capture even partial antagonists of 
PAR1 mediated calcium signaling. Both mitotane and plumbagin are interesting 
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compounds due to their selectivity profiles as well as their molecular size. The simple 
nature of the mitotane and plumbagin molecules favor chemical modification and 
structure activity relationship studies for future enhancement of potency and selectivity 
for PAR1.  Unfortunately, the lipid-like nature of benzyl-dimethyl-tridecyl-ammonium 
complicates any drug discovery efforts, as lipid-like molecules tend to intercalate into the 
membrane non-selectively.  
 The current data set could be re-probed for agonist activity against PAR1. An 
ideal agonist candidate would manifest as a compound that alone produced a calcium 
response but subsequently desensitized PAR1 but not PAR2 or ADP-mediated calcium 
mobilization. The PAR1 agonist with rounds of SAR could produce a high affinity, low 
efficacy agonist deemed a functional antagonist. 
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CHAPTER IV  
 
MITOTANE MODULATES PLATELET ACTIVATION 
 
Introduction 
Mitotane (o,p DDD) is a chemotherapeutic indicated for the treatment of 
inoperable adrenal carcinoma158. Mitotane possesses potent adrenotoxic activity and 
thus was developed as an anti-tumor agent159. Patients with plasma levels above 14 
mg/L have greater survival rate than patients with plasma levels below 14 mg/L. 
Clinically, mitotane acts as an endocrine disruptor possessing estrogenic effects. Part of 
the estrogenic effect in humans has been attributed to increased sex hormone-binding 
globulin and corticosteroid-binding globulin in patients160,161.  Mitotane is also described 
as a 5α reductase inhibitor, and given the role of 5α reductase in dihydroxytestosterone 
biosynthesis, this action likely exacerbates the estrogenic effects of mitotane162.  
Mitotane is also a potent inducer of cytochrome P450 3A4, which among many 
molecules, metabolizes cortisol, thus providing clinical utility for the treatment of 
Cushing’s syndrome, a condition where patients present with excessive cortisol162-164.  
Mitotane also binds several hormone receptors including progesterone receptor, 
estrogen receptor-α and the androgen receptor, though no functional consequence has 
yet been attributed to mitotane binding 165 160.   
Mitotane treatment carries a bleeding side effect in 90% of patients undergoing 
mitotane therapy as documented in two separate studies. In these studies a prolongation 
of bleeding time shortly after treatment begins was reported.  These reports also 
suggested that the bleeding defect was likely due to a defect in platelet function based 
on patients presenting with normal coagulation parameters during treatment, although 
the mechanism of action of mitotane-mediated platelet inhibition remains unknown166,167.  
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Experiments described hereafter determined mitotane inhibits platelet activation ex vivo 
in purified platelets from healthy individuals. Mitotane-mediated platelet inhibition 
manifested as inhibition of agonist-induced αIIbβ3 activation and platelet aggregation. 
This inhibition is rapid in nature and occurs at therapeutic and even sub-therapeutic 
concentrations of mitotane. 
 
Materials and Methods 
 
Reagents 
Purified compounds purchased from Sigma-Aldrich (St. Louis, MO, USA) were 
dissolved in dimethylsulfoxide (DMSO) to a stock concentration of 10 mM and stored at -
20 ºC until used. PAR1 activating peptide (PAR1-AP, SFLLRN) and PAR4 activating 
peptide (PAR4-AP, GYPGKF) were purchased from GL Biochem (Shanghai, China).  
NUNC 384 well plates with black optical bottoms were from Thermo (Rochester, NY, 
USA).  Fluo4-AM was purchased from Invitrogen (Eugene, Oregon, USA).  Fluorescein 
isothiocyanate (FITC) conjugated PAC1 and photoerythrin (PE) conjugated anti-CD62P 
(P-selectin) antibodies were purchased from BD Biosciences (San Jose, CA, USA). 
 
Platelet Preparation 
Human platelets were obtained from healthy volunteers by written consent in 
accordance with, and approved by, the Vanderbilt University Institutional Review Board 
(050182).  Platelets were prepared via standard washed platelet protocol as previously 
described117,118. Briefly, blood from healthy volunteers was drawn into syringes 
containing 3.2% sodium citrate.  Platelet-rich plasma was prepared by centrifugation in a 
Forma 400 ML GP centrifuge at 1100 rpm for 15 minutes.  10X acid citrate dextrose was 
added to platelet-rich plasma and centrifuged at 2400 rpm for 10 minutes.  The 
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supernatant was aspirated and the platelet pellet was suspended in Tyrode’s buffer 
containing 0.1% Bovine Serum Albumin fraction V (BSA) and platelets were counted on 
a Beckman Z1 Coulter particle counter (Brea, CA, USA).   
 
High-throughput platelet calcium assay  
Washed platelets were prepared via standard procedure and suspended in 
Tyrode’s buffer containing 0.1% BSA.  Platelets were dye-loaded for 1 hour with Fluo4-
AM in calcium assay buffer (1X HBSS without calcium or magnesium, 20 mM HEPES, 
2.5 mM probenecid, 1 mM EGTA, 0.1% BSA).  The calcium assay buffer-containing dye 
is mixed with platelets to yield a final concentration of 2.5 µg/mL Fluo4-AM and 1.0x108 
platelets/mL.   60 μL of dye-loaded platelets were added to each well of a NUNC 384 
well black optical bottom plate (Thermo, Rochester, NY, USA).  Fluorescence 
measurements were recorded on a Functional Drug Screening System (FDSS) 6000, 
Hamamatsu (Hamamatsu, Japan) at 37 ºC. 10 μM of each compound was added 6 
minutes prior to the addition of agonist. Liquid handling was performed by the FDSS. 
Experiments were performed in triplicate, on the same plate, from the indicated number 
of donors.  480:540 (ex:em) was measured each second for a total of 12 minutes. The 
final concentration of DMSO in the assay was 0.5%.  The difference between basal 
(defined as t0) and maximal relative fluorescence unit (RFU) values (∆RFUs) f or ex:em 
480:540 was determined for each well. Data are represented as fold over basal for each 
well. Data were plotted in GraphPad PRISM v.5.0. 
 
Flow cytometry 
Briefly, 60 μL of washed platelets at 1.5x107 platelets/mL were added to 
polystyrene tubes. Anti-CD62P antibody or PAC-1 antibody were diluted (per 
manufacturer protocol) in Tyrode’s buffer containing 0.1% BSA. 40 μL of diluted antibody 
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was added to the platelets and incubated for 5 minutes.  Platelets were pre-treated with 
the indicated concentrations of antagonist or DMSO control (0.5%) for 5 minutes 
followed by addition of agonist for 10 minutes. Platelet activity was quenched by the 
addition of ice-cold 1.5% paraformaldehyde followed by dilution in 1X phosphate-
buffered saline. Platelets were analyzed on a BD FACS Canto II (Franklin Lakes, NJ, 
USA). Fluorescent intensity was determined for 100,000 events within the platelet gate. 
Data were collected and analyzed via FACS DiVa software.  100% max response was 
determined for each donor as the DMSO-treated control stimulated with either 200 μM 
PAR4-AP, 20 μM PAR1-AP, or 10 nM thrombin.  Samples treated with inhibitor were 
normalized as a percentage of the DMSO-treated control.  Normalized data were plotted 
in GraphPad PRISM v.5.0. Dose response curves and subsequent IC50 values were 
generated using the ‘log(inhibitor) vs. response variable slope’ parameter.   Data plotted 
are mean±S.E.M. or mean±S.D. 
 
Aggregation 
Briefly, washed platelets were prepared to a final concentration of 2.0x108 
platelets/mL in Tyrode’s buffer containing 0.1% BSA.  Compounds or DMSO control 
(0.1%) were added 10 minutes prior to stimulation with either PAR1-AP or PAR4-AP. 
Light transmittance was recorded by a Chrono-Log Model 700 Aggregometer. 100% light 
transmission signifies full platelet aggregation.   
 
Results 
 
Mitotane inhibits platelet activation 
Platelets from healthy individuals treated ex vivo with 14 mg/L mitotane had 
reduced aggregation responses to thrombin and collagen mediated activation (Figure 
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1A).  Only aggregation mediated by high dose thrombin was not significantly inhibited by 
mitotane.  In addition to aggregation, ATP secretion, indicative of platelet dense granule 
release, downstream of the thrombin and collagen receptors was inhibited by therapeutic 
concentrations of mitotane (Figure 1B).  These data indicate that mitotane has direct 
inhibitory effects on human platelet activation driven by the major platelet agonists, 
thrombin and collagen.   
 
 
Figure 1.  Mitotane inhibits thrombin and collagen mediated platelet activation. 
Platelets were treated with 14 mg/L mitotane for 10 minutes prior to stimulation with 20 
μM PAR1-AP, 200 μM PAR4-AP, 2 nM thrombin (low), 10 nM thrombin (high), or 10 
μg/mL collagen.  A.  Platelet aggregation for agonists represented as % light 
transmittance where 100% transmittance is fully aggregated platelets.  Data represented 
are an n of 6 performed in singlicate mean±S.E.M. B.  ATP release, in nmol, in response 
to platelet agonists with and without treatment with mitotane.  Data presented are an n of 
3 performed in singlicate mean±S.E.M.   
 
 
Mitotane inhibits αIIbβ3 activation in a concentration dependent manner 
To fully characterize the inhibitory effect of mitotane on platelets, αIIbβ3 activation 
was measured.  αIIbβ3 exists on the platelet surface in an inactive conformation and 
upon platelet activation, by a number of agonists, αIIbβ3 undergoes a conformation shift 
to its active state to allow fibrin binding. PAC1 binding measures only receptors in the 
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active conformation. Mitotane treatment alone induces a 4.5 fold increase in active αIIbβ3.  
However, mitotane treatment severely inhibited thrombin and convulxin, a GPVI agonist, 
mediated αIIbβ3 activation (Figure 1A). Furthermore, mitotane inhibition of thrombin, 
PAR1-AP, and PAR4-AP induced αIIbβ3 activation is dose dependent (Figure 1B).  
These data suggest that while mitotane can activate αIIbβ3, subsequent stimulation of the 
platelet does not yield additional receptor activation.   
 
 
Figure 2. Mitotane inhibits αIIbβ3 activation downstream of thrombin receptors.  
Platelets were treated with increasing concentrations of mitotane for 5 minutes followed 
by stimulation with thrombin, 20 μM PAR1-AP, 200 μM PAR4-AP, or 500 ng/mL 
Convulxin (CVX). A. 14 mg/mL mitotane mediated activation or inhibition of agonist 
induced αIIbβ3 activation.  Data represented is and n of at least 3 in singlicate 
mean±S.E.M. B.  Concentration dependence of mitotane inhibition on thrombin mediated 
αIIbβ3 activation.  Data presented is an n of 2 performed in singlicate mean±S.D.  C. 
Concentration dependence of mitotane inhibition on PAR1-AP mediated αIIbβ3 activation. 
N of 3, in singlicate mean±S.E.M. D. Concentration dependence of mitotane inhibition on 
PAR4-AP mediated αIIbβ3 activation. Data displayed is an n of 2 performed in singlicate 
mean±S.D.  
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Mitotane activates alpha granule secretion and calcium mobilization 
 To characterize the effect of mitotane on alpha granule release, P-selectin cell 
surface expression was measured.  P-selectin antigen normally present in the lumen of 
alpha granules is expressed on the platelet surface upon degranulation. Mitotane alone 
appears to fully activate P-selectin cell surface expression such that subsequent 
activation by thrombin, PAR1-AP, PAR4-AP, or convulxin did not produce additional 
alpha granule degranulation (Figure 3A).  Since calcium mobilization is tightly coupled to 
granule secretion, the effect of mitotane on intracellular calcium mobilization was 
measured.  Mitoane alone produced a 10-fold increase in peak calcium mobilization 
(Figure 3B). Mitotane elicited only a modest potentiation of PAR1-AP and PAR4-AP 
peak calcium mobilization, however, the calcium tracing revealed that mitotane greatly 
enhanced the area under the curve for agonist-induced calcium mobilization (Figure 3C).  
 
 Similar chemical entities inhibit PAR-mediated αIIbβ3 activation 
 Mitotane is a de-chlorinated metabolite of the now banned commercial 
insecticide DDT and shares structural similarities, nominally the dual ring structure and 
substituents in the ortho or para positions, with pesticides still in use.  The action of the 
DDT family of compounds and several other chemical species were examined on 
agonist-induced αIIbβ3 activation.  In a concentration dependent manner, 4,4 DDT, 2,4 
DDT, and 4,4 DDD inhibited both PAR1-AP (Figure 4A) and PAR4-AP (Figure 4B) 
mediated αIIbβ3 activation. In addition, a few pesticides with similar chemical structures 
as mitotane that are also approved for commercial use, showed inhibitory action on 
PAR1 mediated αIIbβ3 activation. Chloroflurenol, irgasan, and methoxychlor inhibited 
PAR1-AP mediated αIIbβ3 activation in human platelets (Figure 4C). Chlorofurenol is 
registered for use as an herbicide for the control of broadleaf weeds. Irgasan, also 
known as triclosan is antibiotic and antifungal.  Irgasan is present in consumer products 
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including no-rinse hand sanitizers. Methoxychlor was banned as of 2003, it was used as 
an insecticide replacement for DDT. These data indicate that organochloride insecticides 
particularly those with di-benzene rings may have inhibitory activity on the platelet. 
 
 
Figure 3. Mitotane activates alpha granule secretion and calcium mobilization.  A. 
Platelets treated with mitotane or DMSO control for 5 minutes prior to challenge with 
thrombin, PAR1-AP, PAR4-AP, or convulxin.  N of 2 in singlicate, mean±S.D. B. Peak 
Ca2+ levels of platelets treated with mitotane or DMSO control for 5 minutes prior to 
challenge with thrombin, PAR1-AP, or PAR4-AP. N of 3 in triplicate mean±S.E.M. C. 
Kinetic tracing of PAR1-AP mediated calcium mobilization (black line), 14 mg/L mitotane 
treated platelets (dashed line), or mitotane treated platelets subsequently stimulated with 
PAR1-AP (grey line).  A representative well of each condition from a single donor is 
represented. 
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Figure 4.  Similar chemical entities inhibit PAR mediated αIIbβ3 activation. Platelets 
were treated with increasing concentrations of 4,4, DDD, 2,4 DDT, or 4,4 DDT for 5 
minutes prior to stimulation with either A. 20 μM PAR1-AP or B. 200 μM PAR4-AP n of 1 
or 2 mean±S.D. where indicated.  C. Platelets were treated with 10 μM of the indicated 
pesticides or DMSO control prior to stimulation with 20 μM PAR1-AP.  αIIbβ3 activation 
was measured by flow cytometry.  Data presented is an n of 1 in singlicate.   
 
 
 
Figure 5.  Chemical structures of inhibitory compounds. 
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Summary and Discussion 
Mitotane is a modulator of thrombin and collagen receptor signaling in human 
platelets. Platelets isolated from healthy individuals and acutely treated with therapeutic 
concentrations of mitotane show reduced platelet aggregation in response to thrombin 
receptor agonists and collagen receptor agonists. Patients administered mitotane 
frequently have a bleeding side effect likely resulting from the partial inhibition of 
thrombin and collagen induced αIIbβ3 activation. Furthermore, mitotane inhibits dense 
granule release thus nullifying feed forward purinergic receptor signaling, also a critical 
component for hemostasis, as patients taking clopidogrel have an increased risk of 
bleeding. Interestingly, mitotane alone induces Ca2+ signaling and potentiates peak 
agonist induced Ca2+ mobilization. Mitotane potentiates agonist-induced Ca2+ 
mobilization not by enhancing peak Ca2+, but by initiating calcium release alone and an 
apparent impairment of calcium re-uptake. Due to the efficient coupling between calcium 
mobilization and degranulation, mitotane-mediated calcium enhancement is the probable 
cause for mitotane mediated P-selectin cell surface expression.  It is important to note 
that although mitotane initiated full alpha granule secretion, mitotane inhibited agonist 
induced dense granule secretion, as measured by ATP release. These data interestingly 
suggest that the release of different types of platelet granules may be distinctly regulated 
and thus pharmacologically targeted.   
The dual nature of mitotane action on platelets is likely due to mitotane acting on 
at least two distinct targets.  Key elements of mitotane action that should be addressed 
include the mechanism(s) by which mitotane is causing inhibition of αIIbβ3 activation.  
Structure-activity relationships may be used to separate the inhibitory actions of mitotane 
from the potentiating actions of mitotane to discover a novel class of anti-platelet agents. 
Mitotane could be acting through hormone receptors in the platelet to modulate signaling.  
Mitotane binds several hormone receptors and the platelet expresses several of them 
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including: estrogen receptor β, androgen receptor, mineralocorticoid receptor and the 
glucocorticoid receptor168-170. Initial attempts to pharmacologically ascribe a specific 
hormone receptor to mitotane function proved futile as the hormone receptor antagonists 
alone significantly modulated PAR1-AP mediated platelet activation (data not shown). 
Hormone receptor antagonists are often functional antagonists and can produce agonist 
effects if the concentration of receptor or compound is high enough. Platelet-specific 
knockout mice strategies may be employed to definitively exclude hormone receptors as 
the mechanism through which mitotane is acting. 
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CHAPTER V  
 
SYNTHESIS AND CHARACTERIZATION OF INDOLE DERIVED PAR4 ANTAGONISTS 
 
Introduction 
Thrombin, a key factor in coagulation and inflammation, typically elicits cellular 
responses via activation of protease activated receptors (PARs).  The PAR family 
consists of four GPCRs that are uniquely activated by proteolytic cleavage of the N-
terminus resulting in the generation of a new N-terminus serving as a tethered ligand, 
the endogenous agonist for the receptor75. Human platelets express both PAR1 and 
PAR4.  PAR1 contains a hirudin-like domain that is able to bind thrombin at sub-
nanomolar concentrations however PAR4 lacks this binding domain and is considered 
the low affinity thrombin receptor on platelets115,116,171.  
PAR activation by thrombin in the platelet is responsible for a number of 
responses essential to hemostasis.  Specifically, PAR-mediated platelet activation 
causes rapid intracellular calcium mobilization, secretion of autocrine hormones such as 
5-HT and ADP, the production of eicosanoids such as thromboxane, expression of 
glycoproteins such as P-selectin important for platelet interaction with hematopoetic cells 
involved in coagulation and inflammation, and conversion of the fibrin receptor integrin 
αIIbβ3 to a high affinity conformation.   
PARs are attractive targets for anti-platelet and antithrombotic therapy, as both 
genetic and pharmacological inhibition results in blockade of arterial thrombosis in 
animal models112,121. To date many PAR1 antagonists have been synthesized and 
characterized172-175 and the high affinity non-peptide PAR1 antagonist, Vorapaxar, 
completed phase III clinical trials.  The Vorapaxar TRA-CER trial was terminated due to 
an association of treatment with an increased risk of bleeding including intracranial 
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hemorrhage however, the TRA-2P-TIMI 50 trial, excluding patients presenting with 
previous stroke, was completed and showed that PAR1 antagonism is effective in 
reducing cardiovascular death and ischemic events 105-107. PAR4 as the low affinity 
thrombin receptor is consequently engaged by high concentrations of thrombin and thus 
subject to differential temporal engagement by thrombin. Signaling differences between 
PAR1 and PAR4 are well documented indicating that although activated by the same 
endogenous agonist and purportedly couple to the same G-proteins, platelet thrombin 
receptor signaling is fundamentally distinct60,117-119,176,177.  Though the physiological role 
of PAR1 is becoming clear, the role of PAR4 in thrombosis and hemostasis remains 
unknown due to a lack of a pharmacokinetically, pharmacodynamically sufficient 
antagonists thus the need for potent, selective PAR4 antagonists remains.   
YD-3 is the sole non-peptide, selective, PAR4 receptor antagonist123,125,126,178,179.  
The utility of YD-3 as a PAR4 antagonist has been demonstrated in ex vivo platelet 
assays123,126 as well as an in vivo mouse model of angiogeneisis124. The published 
synthetic route of YD-3 is lengthy, 9 steps beginning from cyclohexanone123.  The 
inactive isomer (N2 instead of N1 of indazole becomes benzylated) comprises at least 
20% of the final yield prohibiting an efficacious synthesis.  A primary goal of a novel 
synthetic route was deletion of the N2 indazole nitrogen and replacement with an indole 
or azaindole, effectively eliminating the formation of the inactive regioisomer.  In parallel, 
efforts were made to survey substituted aryl/heteroaryl moieties in multiple regions of 
YD-3, while also exploring replacements for, and the necessity of, the ethyl ester, a 
potential labile moiety.  In order to rapidly determine structure activity relationships for 
larger libraries of analogs, we also developed a high throughput purified platelet Ca2+ 
assay to measure PAR4 mediated activation of platelets.  There remains improvement 
not only in the synthesis of YD-3 but also in the physiochemical properties of the 
molecule. 
 59 
Materials and Methods 
 
Reagents 
Purified compounds were dissolved in dimethylsulfoxide (DMSO) to a stock 
concentration of 10 mM and stored at -20 ºC until used. PAR1 activating peptide (PAR1-
AP, SFLLRN) and PAR4 activating peptide (PAR4-AP, GYPGKF) were purchased from 
GL Biochem (Shanghai, China).  NUNC 384 well plate black optical bottom was from 
Thermo (Rochester, NY, USA).  Fluo4-AM was purchased from Invitrogen (Eugene, 
Oregon, USA).  Fluorescein isothiocyanate (FITC) conjugated PAC1 and photoerythrin 
(PE) conjugated anti-CD62P (P-selectin) antibodies were purchased from BD 
Biosciences (San Jose, CA, USA).  
 
Platelet Preparation 
Human platelets were obtained from healthy volunteers in accordance with and 
approved by the Vanderbilt University Institutional Review Board (050182).  Written 
informed consent was obtained from all individuals. Platelets were prepared via standard 
washed platelet protocol as previously described117,118. Briefly, blood from healthy 
volunteers (averaging 30 ± 6.6 years of age and comprised of 53% males and 47% 
females) was drawn into syringes containing 3.2% sodium citrate.  Platelet rich plasma 
was prepared by centrifugation in a Forma 400 ML GP centrifuge at 1100 rpm for 15 
minutes.  10X acid citrate dextrose was added to platelet rich plasma and centrifuged at 
2400 rpm for 10 minutes.  The supernatant was aspirated and the platelet pellet was 
suspended in Tyrode’s buffer containing 0.1% Bovine Serum Albumin fraction V (BSA) 
and counted on a Beckman Z1 Coulter particle counter (Brea, CA).  Platelets were used 
at either 2.0x108 or 0.15x108 cells/mL for the two assays. 
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High-throughput platelet calcium assay  
Washed human platelets were prepared via standard procedure and suspended 
in Tyrode’s buffer containing 0.1% BSA.  Platelets were dye loaded for 1 hour with 
Fluo4-AM in calcium assay buffer (1X HBSS without calcium or magnesium, 20 mM 
HEPES, 2.5 mM probenecid, 1 mM EGTA, 0.1% BSA).  The calcium assay buffer 
containing dye is mixed with platelets to yield a final concentration of 2.5 µg/mL Fluo4-
AM and 1.0x108 platelets/mL.   60 μL of dye loaded platelets were added to each well of 
a NUNC 384 well plate black optical bottom plate (Thermo, Rochester, NY, USA).  
Fluorescence measurements were recorded on a Functional Drug Screening System 
(FDSS) 6000, Hamamatsu (Hamamatsu, Japan) at 37 ºC. 10 μM of each compound was 
added 6 minutes prior to the addition of 80 μM PAR4-AP. Compounds were injected by 
the FDSS and occurred simultaneously across each plate. Experiments reported were 
performed in triplicate, on the same plate, from the indicated number of donors.  480:540 
(ex:em) was measured each second for a total of 12 minutes. The final concentration of 
DMSO in the assay was 0.5%.  The difference between basal (defined as t0) and 
maximal relative fluorescence unit (RFU) values (∆RFUs) for ex:em 480:540 was 
determined for each well. The triplicate ∆RFU for DMSO treated control wells stimulated 
with 80 μM PAR4-AP was averaged and the average value ∆ C was set to 100% max 
response for each plate.  Each well was subsequently normalized as a percent of the ∆ C 
control (value/∆C x 100). Normalized data was plotted in GraphPad PRISM v.5.0. 
 
Flow cytometry 
Briefly, 60 μL of washed platelets at a concentration of 1.5x107 platelets/mL were 
added to polystyrene tubes. Anti-CD62P antibody or PAC-1 antibody were diluted (per 
manufacturer protocol) in Tyrode’s buffer containing 0.1% BSA. 40 μL of diluted antibody 
was added to the platelets and allowed to bind for 5 minutes.  Platelets were pre-treated 
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with indicated concentrations of antagonist or DMSO control for 5 minutes followed by 
addition of PAR1-AP or PAR4-AP for 10 minutes.  Platelet activity was quenched by the 
addition ice cold 1.5% paraformaldehyde followed by dilution in 1X phosphate buffered 
saline.  The final DMSO concentration was 0.5%. Platelets were stored up to 18 hours at 
4 ºC before flow cytometric analysis. Analysis was carried out on a BD FACS Canto II 
(Franklin Lakes, NJ, USA). Fluorescent intensity was determined for 100,000 events 
within the platelet gate.  Data was collected and analyzed via FACS DiVa software. 
100% max response was determined for each individual as the DMSO treated control 
stimulated with either 200 μM PAR4-AP, 20 μM PAR1-AP, or 10 nM thrombin.  Samples 
treated with antagonist were normalized as a percentage of the DMSO treated control.  
Normalized data was plotted in GraphPad PRISM v.5.0. Dose response curves and 
subsequent IC50 values were generated using the ‘log(inhibitor) vs. response variable 
slope’ parameter.   Data plotted is mean±S.E.M. or mean±S.D. 
 
Aggregation 
Briefly, washed human platelets were prepared to a final concentration of 2.0x108 
platelets/mL in Tyrode’s buffer containing 0.1% BSA.  Compounds or DMSO control 
were added 10 minutes prior to stimulation with either PAR1-AP or PAR4-AP.  The final 
DMSO concentration was 0.1%.  Light transmittance was recorded by a Chrono-Log 
Model 700 Aggregometer. 100% light transmission signifies full platelet aggregation.   
 
Results 
 
Synthetic scheme for YD-3 and novel compounds 
Although the novel synthetic route allowed for rapid generation of YD-3, the route 
was again subject to formation of an inactive isomer of YD-3 previously described 
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(compound 31 in Chen et al)123. Initially, planning to employ commercially available 3-
bromoindoles and azaindoles, for a rapid two-step route to access analogs of YD-3, it 
was discovered that the 3-bromo analogs proved to be unstable to the reaction 
conditions. Thus, a multi-dimensional iterative parallel synthesis approach was 
employed and an expedient three-step approach was developed (Figure 1), beginning 
with indoles and azaindoles, which were N-alklyated with various commercially available 
benzyl and heteroarylmethyl bromides180,181. A selective bromination in the 3-position 
and a subsequent microwave-assisted Suzuki coupling between brominated indoles and 
heteroaryl boronic acids (Figure 1) delivered YD-3 analogs (APPENDIX B)182 183.  
 
 
 
Figure 1. Synthetic scheme for YD-3 and novel compounds. Reagents and 
conditions.  (a) 1.2 equiv. Ar (Het)CH2Br, 1.2 equiv. NaH, rt, 40 min, 39-65%; (b) 1.1 
equiv. NBS, 4 oC, 16h, 76-90%; (c) 10 mol% Pd2(dba)3, 20 mol% PCy3, 1.1 equiv. 
Ar(Het)B(OH)2 or Ar(Het)B(OR)2, 1.7 equiv. K3PO4, dioxane/H2O, mw, 120 oC, 30 min, 
17-56%.  U,V,W,X,Y,Z = CH or N.  YD-3: U,V,W,X,Y= CH, Z=N, R2=CH2COOCH2CH3 
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High throughput screen identifies novel indole derived PAR4 antagonists 
Protease activated receptor-4 is coupled to Gq and stimulates intracellular 
calcium mobilization in platelets via the dense tubular system as well as lysosome-
related acidic calcium stores35,36. Measurement of intracellular calcium mobilization is a 
common, cost effective practice used to screen for agonists and antagonists of Gq 
coupled GPCRs. Extracellular calcium was withheld in the calcium assay for consistency 
with aggregation and flow cytometry assays, which are also carried out in calcium free 
buffers.  The use of a low concentration of PAR4-AP made it possible to identify low 
affinity competitive inhibitors to better inform future structure activity relationship (SAR) 
studies.  The assay was validated as an acceptable high throughput screening assay 
using the methods of Zhang et al155.  The average Z-factor from two individuals is 0.33 ± 
0.3 (mean±S.D.) demonstrating the assay is sufficient for determining a ‘hit’ (Figure 2A).  
An inhibition time course was performed where samples were treated for increasing 
amounts of time with 10 µM YD-3 and subsequently stimulated with 80 µM PAR4-AP.  
YD-3 significantly inhibited PAR4-AP as early as 1 minute and longer treatment times 
yielded more inhibition (Figure 2B).  However, 6 and 12 minutes of YD-3 treatment did 
not give significantly different levels of inhibition, thus the 6 minute treatment time was 
selected in the interest of shorter total assay time (Figure 2B).  Figure 2C illustrates the 
kinetics of calcium mobilization for platelets stimulated with 80 µM PAR4-AP and how 
YD-3 can slow the mobilization of calcium as well as diminish the maximum change in 
fluorescence (∆RFU). Using the high-throughput calcium mobilization assay and YD-3 
as a control the analogues that were effective at inhibiting a submaximal concentration 
of PAR4 agonist peptide (PAR4-AP) at 10 µM (Figure 2D) was determined.  Similar to 
the SAR reported previously that led to the discovery of YD-3, SAR was very shallow, 
with few analogs displaying activity comparable to YD-3. From 3 rounds of synthesis we 
produced 38 compounds of which 1, 3, 5, VU0469152, VU046154, VU0469155, 
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VU0469907, VU0476680, VU0476683, VU0476684, VU0476686, and VU0476689 were 
capable of inhibiting PAR4 mediated platelet calcium mobilization to less than 50% of 
the maximum response (Figure 2D), indicating that indole was a suitable replacement for 
the indazole core.   Of note, the corresponding carboxylic acid of the terminal ethyl ester, 
2, was inactive as were other ester replacements including 6, and VU0469133-912 
(APPENDIX B).  Of the compounds tested only 1, 3, and 5 were able to fully antagonize 
a maximal PAR4-AP response (Figure 3).  Other ‘hits’ from the screening process did 
not fully antagonize PAR4 mediated αIIbβ3 activation even at 10 µM concentration.  The 
addition of chlorine in the 3 position of YD-3 was shown to give modest improvement in 
the potency of YD-3 for PAR4.  Because of the lack of a terminal ester, attempts were 
made to improve upon the most potent partial antagonist VU0469155, a methoxy ester 
derivative, by adding a chlorine in the meta position of the benzyl group (VU047689). 
There was a modest improvement in the potency against PAR4 but not enough to 
warrant further investigation. 
 
Potency and selectivity of lead compounds 
In human platelets, in addition to receptor mediated calcium mobilization via 
coupling to Gq, PAR stimulation converts the fibrin receptor αIIbβ3 to its high affinity fibrin 
binding conformation, and triggers granule secretion containing P-selectin molecules 
(CD62P). The PAC-1 antibody binds only the high affinity conformation of αIIbβ3 and is 
an accurate readout for αIIbβ3 activation.  Potency of full antagonists was measured 
against both PAR1 and PAR4 mediated αIIbβ3 activation (via PAC-1 binding) and P-
selectin expression (anti-CD62p binding) using flow cytometry.   
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Figure 2. High throughput platelet calcium mobilization identifies novel indole 
derived PAR4 antagonists. A. To determine the Z-factor, and thus the usefulness of 
the assay as a screening tool, platelets were treated with either vehicle (calcium assay 
buffer) or 80 µM PAR4-AP in checkerboard fashion in a 384 well plate.  Representative 
data from 1 donor is displayed as mean ± S.D. using 192 replicates of each condition in 
a single plate.  Z-factor of the represented sample is 0.35 and a second volunteer (data 
not shown) was 0.31. B. Platelets were treated with 10 µM YD-3 for the indicated period 
of time followed by stimulation with 80 µM PAR4-AP.  Data represented is an n of 2 
volunteers, mean ± S.D. performed in triplicate. Means are significantly different where 
indicated. Unpaired one-tailed t-test: time points versus DMSO treated control ***p< 
0.0001.  Unpaired one-tailed t-test: time points versus 12 minute time point #p<0.05.  C. 
Representative tracings of platelets treated with DMSO or 10 µM YD-3 for 6 minutes 
followed by stimulation with 80 µM PAR4-AP. D. Compounds were screened by treating 
platelets with 10 µM compound or DMSO control followed by challenge with 80 µM 
PAR4-AP.  Data represented as percent 80 µM PAR4 response n of 2 volunteers 
mean±S.D.  Compounds that displayed greater than 50% inhibitory activity (below 
dashed line) were subject to further investigation.   
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Figure 3. Structures of full antagonists for PAR4: YD-3, 1, 3, and 5. 
 
There was not any notable functional selectivity between the molecules ability to 
inhibit αIIbβ3 activation (Figure 3, black) and P-selectin expression (Figure 3, grey). 1 
(Figure 4D) was less potent than YD-3 (Figure 4B, Figure S4) at inhibiting PAR4 
mediated responses demonstrating IC50 values for PAR4 mediated αIIbβ3 activation of 66 
± 1 nM versus 26 ± 1 nM respectively. However, YD-3 inhibited PAR1-AP mediated 
αIIbβ3 activation by 55% at 10 µM, a previously undocumented observation (Figure 4A).  
Interestingly, 1 reduced maximum PAR1-AP αIIbβ3 response by 38% (Figure 4C) and 3 
and 5 inhibited PAR1 by 31% (Figure 4E) 56% (Figure 4F) respectively.  Together these 
data suggest that addition of nitrogen into the indole core may contribute to off target 
effects against PAR1.  Both 3 and 5 were significantly less potent then either YD-3 or 1 
with IC50’s for PAR4 mediated αIIbβ3 activation of 1.0 ± 1.1 µM and 170  ± 1 nM 
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respectively (Figure 4F, 4H). These data suggest that indole can serve as a highly 
selective PAR4 inhibitor with only modest loss of potency compared to YD-3.  
 
 
Figure 4. 1, 3, and 5 are full PAR4 antagonists.  1, 3, and 5 were compared with YD-3 
potency against PAR1 and PAR4 mediated αIIbβ3 activation and P-selectin expression. 
Platelets were treated with compound or DMSO control for 5 minutes prior to stimulation 
with 20 µM PAR1-AP (left panels) or 200 µM PAR4-AP (right panels) for 10 minutes. 
αIIbβ3 activation (black) and P-selectin expression (grey) in PAR activated platelets by 
flow cytometry.  The order of potency for PAR4 antagonism is YD-3>1>5>3. Values are 
displayed as mean±S.E.M. n of 3 volunteers performed in singlicate.   
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The PAR4 partial antagonists: VU0469152, VU046154, VU0469155, 
VU0469907, VU0476680, VU0476683, VU0476684, VU0476686, and VU0476689, 
displayed a similar magnitude of inhibition against PAR1 mediated platelet activation as 
YD-3, 1, 3, and 5 (Figure 5) however, because these compounds did not fully antagonize 
PAR4 mediated platelet responses even at 10 µM, the additional loss of selectivity 
indicates poor lead compounds.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
 
Figure 5. Several compounds act as partial antagonists of PAR4. Platelets were 
treated with indicated concentrations of compound for 5 minutes prior to stimulation with 
200 µM PAR4-AP.  αIIbβ3 activation was measured via flow cytometric analysis of PAC1 
binding.  Hits from the second round (A) and third round (B) of optimization are shown.  
Data is presented as mean±S.D. n of 2 volunteers.   
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Potency of compounds against thrombin mediated platelet activation 
Inhibition of the PAR4-AP does not completely describe the potency of any PAR4 
antagonist.  Compounds should elicit an inhibitory effect against thrombin either alone or 
in combination with a PAR1 antagonist, such as RWJ-56110173.  Against a high dose of 
thrombin where both PAR1 and PAR4 are engaged, PAR4 antagonists alone cannot 
significantly inhibit thrombin mediated αIIbβ3 activation 171.  The ability of 1 µM YD-3, 1µM 
1, 3.16 µM 3, and 1 µM 5 to inhibit thrombin mediated αIIbβ3 activation at concentrations 
where each compound previously demonstrated complete inhibition of PAR4 mediated 
αIIbβ3 activation and low inhibition for PAR1 mediated αIIbβ3 activation was subsequently 
tested.  YD-3, 1, 3, and 5 were able to reduce PAR1 mediated αIIbβ3 activation by 8.4 ± 
2.4%, 14.1 ± 2.8%, 7.2 ± 1.3%, and 7.2 ± 1.4% respectively when used at these lower 
concentrations (Figure 4A, C, E, G).  10 µM RWJ-56110 alone was able to significantly 
inhibit thrombin mediated αIIbβ3 activation by 18.4 ± 5.4% and when used in combination 
with either YD-3 or 1, was able to reduce thrombin mediated signaling by 42.9 ± 9.7% 
and 37.1 ± 6.4% respectively (Figure 6). RWJ and YD-3 demonstrated dual inhibition of 
PAR1 and PAR4 against thrombin since the experimentally determined reduction in 
thrombin mediated αIIbβ3 activation by the combination of RWJ and YD-3 (42.9 ± 9.7%) 
was greater than the addition of the effect of RWJ-56110 on thrombin and the effect of 
YD-3 on PAR1-AP (26.8 ± 6.0%). Compound 1 in conjunction with RWJ-56110 also 
slightly inhibited thrombin mediated αIIbβ3 activation to a greater extent than addition of 
the inhibitory effects of each alone (37.1 ± 6.4% compared to 32.5 ± 6.1%).  Neither 3 
(14 ± 2% reduction) nor 5 (17 ± 2% reduction) when added in conjunction with RWJ-
56110 were able to inhibit thrombin mediated platelet αIIbβ3 activation to a greater 
magnitude than RWJ-56110 alone.  These data suggest that even slight losses of 
antagonist potency against PAR4-AP responses translates into dramatic reductions in 
potency against thrombin.  Additionally, these data suggest that for platelets stimulated 
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with high concentrations of thrombin, the contribution of PAR1 signaling to αIIbβ3 
activation is greater than PAR4. 
 
 
Figure 6. Dual PAR1/PAR4 inhibition significantly inhibits thrombin mediated 
platelet activation.  Platelets were treated with PAR1 antagonist RWJ-56110 or PAR4 
full antagonists either alone or in combination prior to stimulation with 10 nM thrombin for 
10 minutes.  αIIbβ3 activation was measured, data reported is mean±S.E.M. n of 3 
volunteers.  One sample t-test for significant deviation from DMSO control p-values 
*p<0.05, **p<0.005. 
 
 
Lead compounds inhibit PAR-AP mediated aggregation 
The activities of the full antagonists YD-3, 1, 3, and 5, were assessed via 
classical measurement of platelet activity, platelet aggregation.  We demonstrate using 
YD-3 as a control, 1, and 5 are able to significantly inhibit PAR4 but not PAR1 mediated 
platelet aggregation in healthy subjects (Figure 7).  Compound 3 also inhibits PAR4 
mediated platelet aggregation versus PAR1 mediated platelet aggregation though non-
significantly (p=0.054).   
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Figure 7. Full PAR4 antagonists are selective for PAR4 mediated platelet 
aggregation. Platelets were treated with YD-3, 1, 3 or 5 for 10 minutes prior to 
stimulation with either 20 µM PAR1-AP (white bars) or 200 µM PAR4-AP (black bars).  
Data reported as % light transmittance where 100% represents fully aggregated 
platelets. Unpaired two-tailed t-test versus DMSO treated agonist control. Data displayed 
as mean±S.E.M n of 3 or more. Means are significantly different where indicated. *** 
p<0.0001, * p<0.05. 
 
 
Mechanism of action of YD-3 and compound 1 
To examine the putative mechanism of action of the most potent antagonists, 
YD-3 and 1, PAR4-AP mediated P-selectin cell surface expression was measured to 
generate highly descriptive twelve point CRCs in the presence of increasing 
concentrations of antagonist.  YD-3 is previously described as competitive in nature by 
platelet aggregation126.  This finding was confirmed by P-selectin expression.  Figure 8 
shows parallel rightward shifts in the PAR4 CRC in response to increasing 
concentrations of compound, indicative of a competitive mechanism of action for both 
YD-3 (Figure 8A) and 1 (Figure 8B).   
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Figure 8. YD-3 and 1 act as competitive antagonists against PAR4.  Platelets were 
treated with indicated concentrations of A) YD-3 or B) 1 for 5 minutes prior to stimulation 
with a full PAR4-AP concentration response curve.  P-selectin was measured via flow 
cytometry.  Data represented as mean±S.E.M n of 3.   
 
 
Summary and Discussion 
These data indicate that indole is a suitable scaffold for selective inhibitory 
activity against PAR4 mediated platelet activation and thus serve as a novel scaffold 
with which to build future PAR4 antagonists. Given the large number of commercially 
available derivatives of indole, bromides, aryl boronic acids and boronic esters, the 
synthetic routes presented are capable of rapidly generating numerous compounds. The 
use of a high throughput purified platelet calcium mobilization assay allows for rapid 
identification of molecules with inhibitory activity towards PAR4.  Compound 1 retains 
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antagonist activity against both the PAR4 peptide as well as thrombin and as such is the 
most potent novel compound presented here. The other scaffolds 3 (2-pyridine) and 5 
(7-azaindole), retained selectivity for PAR4 versus PAR1 but sacrificed potency against 
PAR4 activating peptide and most importantly thrombin.  Both YD-3 and, to a lesser 
extent, 1 display weak off-target effects against PAR1. The inability of compounds 1, 3, 
and 5 to fully inhibit PAR4 mediated platelet aggregation is reflective not of partial 
inhibition of the response but rather that a couple individuals fully aggregated (though 
slowly) in the presence of 1, 3, or 5.  This phenomenon is likely reflective of the loss of 
affinity of these compounds for PAR4. The apparent discrepancy of YD-3 selectivity for 
PAR4 versus PAR1 between platelet aggregation assays and flow cytometric analysis 
(αIIbβ3 activation) can be at least partially explained by signaling convergence. PAR 
mediated aggregation is dependent on αIIbβ3 activation; however, ADP signaling, 
calcium mobilization, and granule secretion also play a significant role117. Additionally, 
there is evidence that thrombin mediated platelet aggregation, particularly PAR1-AP 
stimulated platelet aggregation, is resistant to αIIbβ3 blockade 184,185. Gawaz et al. 
demonstrate using direct αIIbβ3 blockade that approximately 50% of total αIIbβ3 receptor 
is sufficient for TRAP (PAR1-AP) to elicit 80% of maximum TRAP mediated aggregation. 
Thus, inhibition of 55% of PAR1-AP mediated αIIbβ3 activation may not be enough to 
inhibit PAR1 mediated platelet aggregation184. 
Thrombin mediated αIIbβ3 activation was not abolished even when both 
antagonists were added prior to stimulation. One possible explanation is that thrombin 
binds GPIb receptors, which may contribute to signaling186. Of note, other than YD-3, 
PAR4 antagonists did not have a large effect against thrombin when putative PAR1 off 
target effects were accounted for.  A probable rationale for this observation is that 
thrombin activated protease activated receptors create tethered ligands which are 
essentially irreversible agonists such that any orthosteric molecule must be either 
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irreversible, or have such high affinity that the displacement of the tethered ligand is 
possible. Alternatively, one could envision that negative allosteric modulators may prove 
to be a better approach to inhibit thrombin activated PARs.  Though we have identified 
indole as a favorable scaffold for future production of PAR4 antagonists, there is 
considerable room for improvement for antagonists of PAR4 and as such, efforts are 
underway to discover higher potency compounds. 
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CHAPTER VI 
 
SYNOPSIS 
 
Targeting thrombin receptors 
The targeting of thrombin receptors, PAR1 and PAR4, for therapeutic 
intervention truly represents interesting challenges for drug discovery and design.  First, 
the irreversible activation by thrombin will require antagonists be very high affinity (likely 
in the form of low dissociation) to be efficacious, or like Vorapaxar, bind irreversibly to 
the receptor. An alternative strategy, particularly for PAR1 antagonism, may be 
functional antagonism. Since PAR1 when activated is rapidly sorted to lysosomes for 
degradation and is not recycled to the cell surface, a high affinity, low efficacy partial 
agonist would serve as a functional antagonist, as long as the agonist shifted the 
receptor into a state that induced phosphorylation.  For either PAR1 or PAR4 an ideal 
strategy for receptor inhibition is allosteric modulation such that instead of attempting to 
compete for tethered ligand binding, the negative allosteric modulator induces a receptor 
conformation which precludes tethered ligand binding, enhances the tethered ligand off 
rate, reduces the tethered ligand on-rate or reduces the receptor- G-protein coupling 
efficiency of tethered agonist induced activation. Furthermore, since irreversible PAR1 
inhibition has been shown to be relatively safe in humans, antibody based therapeutics 
may be considered.  Antibodies directed towards the hirudin-like binding domain on 
PAR1 or spanning the cleavage site of either receptor would provide the most 
efficacious antibodies. Off-target issues with prolonged PAR1 antagonism are likely to 
arise since PAR1 expression is ubiquitous, for instance murine models demonstrate the 
necessity of functional PAR1 for embryonic development. The restricted expression 
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profile of PAR4 however, is amenable to irreversible or long-term antagonist 
interventions. 
The feasibility for discovering each class of inhibitors presents a separate 
challenge and in the case of PAR4 is presently impossible due to lack of sufficient tool 
compounds. High-throughput functional screens can identify antagonists, negative 
allosteric modulators, and partial agonists. Partial agonist leads can be counter screened 
to ensure selectivity and that they induce receptor phosphorylation. Subsequent 
medicinal chemistry efforts could improve the affinity of inhibitors or partial agonist 
compounds and, in the case of PAR1, the mechanism can be described as competitive 
or non-competitive for ligand binding, and affinity could be determined. PAR1 drug 
discovery efforts are aided by the availability of a radiolabeled high affinity agonist 
peptide, whereas PAR4 lacks this tool. At present YD-3 and compound 1 are described 
as competitive only by function, not ligand binding, therefore these compounds may not 
be acting at the level of the receptor which may manifest as off target effects once 
administered in vivo. Furthermore, the lack of a radioligand probe, particularly antagonist 
probe, for PAR4 reduces the amount of pharmacological information that can be 
gathered.  With a suitable probe, PAR4 inhibitors could be described as competitive or 
non-competitive at the receptor. Furthermore, PAR4 expression levels on platelets, 
cancer cells, and in murine models could be accurately described. While the 
understanding of PAR1 in human physiology and disease is burgeoning, it is imperative 
that an acceptable PAR4 antagonist probe be developed so that understanding of the 
receptor and its contribution to thrombosis and hemostasis is better understood. 
 
Progress towards the specific aims 
 We made considerable progress on the specific aims as outlined in Chapter I. 
We successfully synthesized YD-3 by two distinct routes having either two or three 
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steps.  By converting to the indole scaffold thus eliminating the nitrogen in the 2 position 
of the indole ring, we effectively eliminated the formation of the inactive isomer of YD-3. 
We synthesized a library of over 30 compounds, screened them in a high-throughput 
calcium assay, and characterized potency by measurement of both integrin αIIbβ3 
activation and P-selectin secretion.  Although none of the compounds were more potent 
than YD-3, valuable SAR data about the pharmacophore was gathered.  The indole ring 
tolerates nitrogen substitutions, while the ethyl ester seems required for low nanomolar 
potency.  Although we could not use radioligands to determine the mechanism of action 
of our novel compounds, we performed Schild analysis in an effort to classify molecules 
as competitive or non-competitive.  Both YD-3 and lead Compound 1 displayed 
competitive behavior against the PAR4-AP.  However, allosteric compounds or 
compounds which work downstream of the receptor may also appear competitive in 
functional assays, thus the mechanism of action of PAR4 antagonists remains 
undefined. Due to the compounds lack of favorable pharmacokinetic profiles, 
synthesized compounds were not subject to testing in ex vivo models of thrombosis. 
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